US20170312287A1 - Dpp iv inhibitor formulations - Google Patents
Dpp iv inhibitor formulations Download PDFInfo
- Publication number
- US20170312287A1 US20170312287A1 US15/655,269 US201715655269A US2017312287A1 US 20170312287 A1 US20170312287 A1 US 20170312287A1 US 201715655269 A US201715655269 A US 201715655269A US 2017312287 A1 US2017312287 A1 US 2017312287A1
- Authority
- US
- United States
- Prior art keywords
- pharmaceutical composition
- tablet
- diluent
- film
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- HDARIOSGMVVPLE-LJQANCHMSA-N CC#CCN1C(N2CCC[C@@H](N)C2)=NC2=C1C(=O)N(CC1=C(C#N)C=C3C=CC=CC3=N1)C(=O)N2C Chemical compound CC#CCN1C(N2CCC[C@@H](N)C2)=NC2=C1C(=O)N(CC1=C(C#N)C=C3C=CC=CC3=N1)C(=O)N2C HDARIOSGMVVPLE-LJQANCHMSA-N 0.000 description 2
- LTXREWYXXSTFRX-QGZVFWFLSA-N CC#CCN1C(N2CCC[C@@H](N)C2)=NC2=C1C(=O)N(CC1=NC3=CC=CC=C3C(C)=N1)C(=O)N2C Chemical compound CC#CCN1C(N2CCC[C@@H](N)C2)=NC2=C1C(=O)N(CC1=NC3=CC=CC=C3C(C)=N1)C(=O)N2C LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 description 2
- 0 [1*]N1C(=O)C2=C(N=C([2*])N2CC#CC)N(C)C1=O Chemical compound [1*]N1C(=O)C2=C(N=C([2*])N2CC#CC)N(C)C1=O 0.000 description 2
- BNPBEDWUQOSRHB-UHFFFAOYSA-N CC#CCN1C(N(C)CC(C)(C)N)=NC2=C1C(=O)N(CC1=NC3=C(C=CC=C3)C(C)=N1)C(=O)N2C Chemical compound CC#CCN1C(N(C)CC(C)(C)N)=NC2=C1C(=O)N(CC1=NC3=C(C=CC=C3)C(C)=N1)C(=O)N2C BNPBEDWUQOSRHB-UHFFFAOYSA-N 0.000 description 1
- OWVQLTBTGFYAHU-HNNXBMFYSA-N CC#CCN1C(N(C)C[C@H](C)N)=NC2=C1C(=O)N(CC1=NC3=C(C=CC=C3)C(C)=N1)C(=O)N2C Chemical compound CC#CCN1C(N(C)C[C@H](C)N)=NC2=C1C(=O)N(CC1=NC3=C(C=CC=C3)C(C)=N1)C(=O)N2C OWVQLTBTGFYAHU-HNNXBMFYSA-N 0.000 description 1
- ZOTODWFVYUPZFO-GOSISDBHSA-N CC#CCN1C(N2CCC[C@@H](N)C2)=NC2=C1C(=O)N(CC1=C(C#N)C=CC=C1)C(=O)N2C Chemical compound CC#CCN1C(N2CCC[C@@H](N)C2)=NC2=C1C(=O)N(CC1=C(C#N)C=CC=C1)C(=O)N2C ZOTODWFVYUPZFO-GOSISDBHSA-N 0.000 description 1
- ISVBJQYIQQKSGK-MRXNPFEDSA-N CC#CCN1C(N2CCC[C@@H](N)C2)=NC2=C1C(=O)N(CC1=C(C#N)C=CC=N1)C(=O)N2C Chemical compound CC#CCN1C(N2CCC[C@@H](N)C2)=NC2=C1C(=O)N(CC1=C(C#N)C=CC=N1)C(=O)N2C ISVBJQYIQQKSGK-MRXNPFEDSA-N 0.000 description 1
- GFMVACPPQCXLGW-QGZVFWFLSA-N CC#CCN1C(N2CCC[C@@H](N)C2)=NC2=C1C(=O)N(CC1=CC3=NC=CN=C3C=C1)C(=O)N2C Chemical compound CC#CCN1C(N2CCC[C@@H](N)C2)=NC2=C1C(=O)N(CC1=CC3=NC=CN=C3C=C1)C(=O)N2C GFMVACPPQCXLGW-QGZVFWFLSA-N 0.000 description 1
- ONMDRNPIEXAJEZ-MRXNPFEDSA-N CC#CCN1C(N2CCC[C@@H](N)C2)=NC2=C1C(=O)N(CC1=NC(C)=CC(C)=N1)C(=O)N2C Chemical compound CC#CCN1C(N2CCC[C@@H](N)C2)=NC2=C1C(=O)N(CC1=NC(C)=CC(C)=N1)C(=O)N2C ONMDRNPIEXAJEZ-MRXNPFEDSA-N 0.000 description 1
- HAKJUVBTRWXTRU-QGZVFWFLSA-N CC#CCN1C(N2CCC[C@@H](N)C2)=NC2=C1C(=O)N(CC1=NC3=CC=CC=C3C(C)=N1)N=C2 Chemical compound CC#CCN1C(N2CCC[C@@H](N)C2)=NC2=C1C(=O)N(CC1=NC3=CC=CC=C3C(C)=N1)N=C2 HAKJUVBTRWXTRU-QGZVFWFLSA-N 0.000 description 1
- ILTRPILDWNCOMQ-QGZVFWFLSA-N CC#CCN1C(N2CCC[C@@H](N)C2)=NC2=C1C(=O)N(CC1=NC3=CC=CC=C3C=N1)C(=O)N2C Chemical compound CC#CCN1C(N2CCC[C@@H](N)C2)=NC2=C1C(=O)N(CC1=NC3=CC=CC=C3C=N1)C(=O)N2C ILTRPILDWNCOMQ-QGZVFWFLSA-N 0.000 description 1
- TTYUNRVFZJWXHB-MRXNPFEDSA-N CC#CCN1C(N2CCC[C@@H](N)C2)=NC2=C1C(=O)N(CC1=NC3=CC=CN=C3C=C1)C(=O)N2C Chemical compound CC#CCN1C(N2CCC[C@@H](N)C2)=NC2=C1C(=O)N(CC1=NC3=CC=CN=C3C=C1)C(=O)N2C TTYUNRVFZJWXHB-MRXNPFEDSA-N 0.000 description 1
- YLTXBUGZVMPESA-OAHLLOKOSA-N CC#CCN1C(N2CCC[C@@H](N)C2)=NC2=C1C(=O)N(CC1=NC=CC(C)=N1)C(=O)N2C Chemical compound CC#CCN1C(N2CCC[C@@H](N)C2)=NC2=C1C(=O)N(CC1=NC=CC(C)=N1)C(=O)N2C YLTXBUGZVMPESA-OAHLLOKOSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
Definitions
- the present invention relates to pharmaceutical compositions of selected DPP IV inhibitors, their preparation and their use to treat selected medical conditions.
- DPP-IV dipeptidyl peptidase IV
- CD26 The enzyme DPP-IV (dipeptidyl peptidase IV) also known as CD26 is a serine protease known to lead to the cleavage of a dipeptide from the N-terminal end of a number of proteins having at their N-terminal end a prolin or alanin residue. Due to this property DPP-IV inhibitors interfere with the plasma level of bioactive peptides including the peptide GLP-1 and are considered to be promising drugs for the treatment of diabetes mellitus.
- DPP-IV inhibitors with a primary or secondary amino group show incompatibilities, degradation problems, or extraction problems with a number of customary excipients such as microcrystalline cellulose, sodium starch glycolate, croscarmellose sodium, tartaric acid, citric acid, glucose, fructose, saccharose, lactose, maltodextrines.
- customary excipients such as microcrystalline cellulose, sodium starch glycolate, croscarmellose sodium, tartaric acid, citric acid, glucose, fructose, saccharose, lactose, maltodextrines.
- the compounds themselves are very stable, they react with many excipients used in solid dosage forms and with impurities of excipients, especially in tight contact provided in tablets and at high excipient/drug ratios.
- a pharmaceutical composition according to the present invention is intended for the treatment of to achieve glycemic control in a type 1 or type 2 diabetes mellitus patient and comprises a DPP-IV inhibitor with an amino group, especially a free or primary amino group, as an active ingredient, a first and second diluent, a binder, a disintegrant and a lubricant.
- An additional disintegrant and an additional glidant are a further option.
- the compositions can be used to treat rheumatoid arthritis, obesity and osteoporosis as well as to support allograft transplantation.
- Diluents suitable for a pharmaceutical composition according to the invention are cellulose powder, dibasic calciumphosphate anhydrous, dibasic calciumphosphate dihydrate, erythritol, low substituted hydroxypropyl cellulose, mannitol, pregelatinized starch or xylitol. Among those diluents mannitol and pregelatinized starch are preferred.
- Diluents preferred as the second diluent are the above mentioned diluents pre-gelatinized starch and low-substituted hydroxypropylcellulose (L-HPC) which show additional binder properties.
- Lubricants suitable for a pharmaceutical composition according to the invention are talc, polyethyleneglycol, calcium behenate, calcium stearate, hydrogenated castor oil or magnesium stearate.
- the preferred lubricant is magnesium stearate.
- Binders suitable for a pharmaceutical composition according to the invention are copovidone (copolymerisates of vinylpyrrolidon with other vinylderivates), hydroxypropyl methylcellulose (HPMC), hydroxypropylcellulose (HPC), polyvinylpyrrolidon (povidone), pregelatinized starch, low-substituted hydroxypropylcellulose (L-HPC), copovidone and pregelatinized starch being preferred.
- binders pregelatinized starch and L-HPC show additional diluent and disintegrant properties and can also be used as the second diluent or the disintegrant.
- Disintegrants suitable for a pharmaceutical composition according to the present invention are corn starch, crospovidone, low-substituted hydroxypropylcellulose (L-HPC) or pregelatinized starch, corn starch being preferred.
- colloidal silicon dioxide can be used as an optional glidant colloidal silicon dioxide.
- An exemplary composition according to the present invention comprises the diluent mannitol, pregelatinized starch as a diluent with additional binder properties, the binder copovidone, the disintegrant corn starch, and magnesium stearate as the lubricant.
- Dosage forms prepared with a pharmaceutical compositions according to the present invention contain active ingredients in dosage ranges of 0.1-100 mg. Preferred dosages are 0.5 mg, 1 mg, 2.5 mg, 5 mg and 10 mg.
- Typical pharmaceutical compositions comprise (% by weight)
- Preferred pharmaceutical compositions comprise (% by weight)
- compositions according to the invention are intended for oral use and can be used in the dosage form of a capsule, a tablet or a film-coated tablet.
- the film coat represents 2-4%, preferably 3% of the composition and comprises a film-forming agent, a plasticizer, a glidant and optionally one or more pigments.
- An exemplary coat composition may comprise hydroxypropylmethylcellulose (HPMC), polyethylene glycol (PEG), talc, titanium dioxide and optionally iron oxide.
- DPP-IV inhibitors with a primary amino group and salts thereof such as any DPP-IV inhibitor and salt thereof defined by formula (I)
- R1 is ([1,5]naphthyridin-2-yl)methyl, (quinazolin-2-yl)methyl], (quinoxalin-6-yl)methyl, (4-Methyl-quinazolin-2-yl)methyl, 2-Cyano-benzyl, (3-Cyano-quinolin-2-yl)methyl, (3-Cyano-pyridin-2-yl)methyl, (4-Methyl-pyrimidin-2-yl)methyl, or (4,6-Dimethyl-pyrimidin-2-yl)methyl, and R2 is 3-(R)-amino-piperidin-1-yl, (2-amino-2-methyl-propyl)-methylamino or (2-(S)-amino-propyl)-methylamino.
- Preferred DPP IV inhibitor compounds are the following compounds and salts thereof:
- compositions according to the invention can be prepared by a wet granulation process.
- Alternative methods for granulation of active ingredient and excipients with a granulation liquid are fluid bed granulation or one-pot granulation.
- the granulation liquid is a solvent such as water, ethanol, methanol, isopropanol, acetone, preferably purified water, and contains a binder such as copovidone.
- the solvent is a volatile component, which does not remain in the final product.
- the active ingredient and the other excipients with exception of the lubricant are premixed and granulated with the aqueous granulation liquid using a high shear granulator.
- the wet granulation step is followed by an optional wet sieving step, drying and dry sieving of the granules. For example a fluid bed dryer can then be used for drying.
- the dried granules are sieved through an appropriate sieve.
- a suitable conventional blender such as a free fall blender followed by addition of the lubricant such as magnesium stearate and final blending in the blender.
- an exemplary wet granulation process for the preparation of a pharmaceutical composition according to the present invention comprises
- drying the granulate at about 40-75° C. and preferably 55-65° C. inlet air temperature for example in a fluid bed dryer until the desired loss on drying value in the range of 1-5% is obtained;
- delumping the dried granulate for example by sieving through a sieve with a mesh size of 0.6 mm-1.6 mm, preferably 1.0 mm;
- part of the excipients such as part of a disintegrant (e.g. corn starch) or a diluent (e.g. pregelatinized starch) or an additional disintegrant (crospovidone) can be added extragranular prior to final blending of step g.
- a disintegrant e.g. corn starch
- a diluent e.g. pregelatinized starch
- crospovidone crospovidone
- the granulate produced in steps a to e is produced in a one pot high shear granulation process and subsequent drying in a one pot granulator.
- the final blend is further filled into capsules.
- the final blend is further compressed into tablets of the target tablet core weight with appropriate size and crushing strength, using an appropriate tablet press.
- a coating suspension is prepared and the compressed tablet cores are coated with the coating suspension to a weight gain of about 2-4%, preferably about 3%, using a standard film coater.
- the film-coating solvent is a volatile component, which does not remain in the final product.
- An active DPP IV inhibitor ingredient with a primary amino group and all other excipients with exception of magnesium stearate are blended in a high shear blender. This pre-mix is sieved through a 1 mm sieve. After addition of magnesium stearate the pre-mix is blended in a free fall blender to produce the final blend. The final blend is compressed into tablets using a suitable tablet press.
- the following compositions can be obtained:
- Component mg/tablet %/tablet mg/tablet %/tablet Active ingredient 1.000 2.000 2.500 2.000 Mannitol 43.250 86.500 108.125 86.500 Pregelatinized starch 5.000 10.000 12.500 10.000 Magnesium stearate 0.750 1.500 1.875 1.500 Total 50.000 100.000 125.000 100.000
- Component mg/tablet %/tablet mg/tablet %/tablet Active ingredient 5.000 2.000 10.000 2.000 Mannitol 216.250 86.500 432.500 86.500
- An active DPP IV inhibitor ingredient with a primary amino group and all other excipients with exception of magnesium stearate are blended in a high shear blender. This pre-mix is sieved through a 1 mm sieve. After addition of magnesium stearate the pre-mix is blended in a free fall blender to produce the final blend. The final blend is compressed into tablets using a suitable tablet press.
- the following compositions can be obtained:
- Component mg/tablet %/tablet mg/tablet %/tablet Active ingredient 10.000 1.667 10.000 2.222 Dibasic 464.000 77.333 344.000 76.788 calciumphosphate, anhydrous Low-substituted 120.000 20.000 90.000 20.000 hydroxypropylcellulose Magnesium stearate 6.000 1.000 6.000 1.000 Total 600.000 100.000 450.000 100.000
- Copovidone is dissolved in purified water at ambient temperature to produce a granulation liquid.
- An active DPP IV inhibitor ingredient with a primary amino group, mannitol and part of the pregelatinized starch are blended in a suitable mixer, to produce a pre-mix.
- the pre-mix is moistened with the granulation liquid and subsequently granulated.
- the moist granulate is optionally sieved through a sieve with a mesh size of 1.6-3.0 mm.
- the granulate is dried at 55° C. in a suitable dryer to a residual moisture content corresponding to 2-5% loss on drying.
- the dried granulate is sieved through a sieve with a mesh size of 1.0 mm.
- the granulate is blended with part of the pregelatinized starch in a suitable mixer.
- Magnesium stearate is added to this blend after passing through a 1.0 mm sieve for delumping.
- the final blend is produced by final blending in a suitable mixer and compressed into tablets.
- the following tablet composition can be obtained:
- Copovidone is dissolved in purified water at ambient temperature to produce a granulation liquid.
- An active DPP IV inhibitor ingredient with a primary amino group, mannitol, pregelatinized starch and corn starch are blended in a suitable mixer to produce the pre-mix.
- the pre-mix is moistened with the granulation liquid and subsequently granulated using a high shear mixer.
- the moist granulate is optionally sieved through a sieve with a mesh size of 1.6-3.0 mm.
- the granulate is dried at about 60° C. in a fluid bed dryer until a loss on the drying value of 2-4% is obtained.
- the Final Blend is compressed into tablet cores.
- Hydroxypropyl methylcellulose, polyethylene glycol, talc, titanium dioxide and iron oxide are suspended in purified water in a suitable mixer at ambient temperature to produce a coating suspension.
- the tablet cores are coated with the coating suspension to a weight gain of about 3% to produce film-coated tablets.
- the following tablet compositions can be obtained:
- Copovidone is dissolved in purified water at ambient temperature to produce a granulation liquid.
- An active DPP IV inhibitor ingredient with a primary amino group, mannitol and pregelatinized starch are blended in a suitable mixer to produce a pre-mix.
- the pre-mix is moistened with the granulation liquid and subsequently granulated.
- the moist granulate is optionally sieved through a suitable sieve.
- the granulate is dried at about 50° C. in a suitable dryer until a loss on drying value of 3-5% is obtained.
- the dried granulate is sieved through a sieve with a mesh size of 1.0 mm.
- Magnesium stearate is passed through a 1.0 mm sieve and added to the granulate. Subsequently the final blend is produced by final blending in a suitable blender and the final blend is compressed into tablets.
- the following tablet compositions can be obtained:
- Copovidone is dissolved in purified water at ambient temperature to produce a granulation liquid.
- An active DPP IV inhibitor ingredient with a primary amino group and a part of mannitol, pregelatinized starch and corn starch are blended in a suitable mixer, to produce a pre-mix.
- the pre-mix is moistened with the granulation liquid and subsequently granulated.
- the moist granulate is sieved through a suitable sieve.
- the granulate is dried at about 60° C. inlet air temperature in a fluid bed dryer until a loss on drying value of 1-4% is obtained.
- the dried granulate is sieved through a sieve with a mesh size of 1.0 mm.
- Magnesium stearate is passed through a sieve for delumping and added to the granulate. Additionally the remaining part of the excipients are added extragranular at this process step. Subsequently the final blend is produced by final blending in a suitable blender and compressed into tablet cores.
- Hydroxypropyl methylcellulose, polyethylene glycol, talc, titanium dioxide and iron oxide are suspended in purified water in a suitable mixer at ambient temperature to produce a coating suspension.
- the tablet cores are coated with the coating suspension to a weight gain of about 3% to produce film-coated tablets.
- the following formulation variants can be obtained:
- Formulation E Component mg/Tablet %/Tablet mg/Tablet %/Tablet Active ingredient 1.000 1.111 1.000 1.111 Mannitol 23.300 25.889 66.950 74.389 Pregelatinized starch 4.500 5.000 4.500 5.000 Corn starch 4.500 5.000 4.500 5.000 Copovidone 1.350 1.500 2.700 3.000 Total (granulate) 34.650 38.500 79.650 88.500 Corn starch 4.500 5.000 4.500 5.000 4.500 5.000 Mannitol 45.000 50.000 Magnesium stearate 1.350 1.500 1.350 1.500 Total (tablet core) 90.000 100.000 90.000 100.000 100.000
Abstract
The present invention relates to pharmaceutical compositions of DPP IV inhibitors with an amino group, their preparation and their use to treat diabetes mellitus.
Description
- The present invention relates to pharmaceutical compositions of selected DPP IV inhibitors, their preparation and their use to treat selected medical conditions.
- The enzyme DPP-IV (dipeptidyl peptidase IV) also known as CD26 is a serine protease known to lead to the cleavage of a dipeptide from the N-terminal end of a number of proteins having at their N-terminal end a prolin or alanin residue. Due to this property DPP-IV inhibitors interfere with the plasma level of bioactive peptides including the peptide GLP-1 and are considered to be promising drugs for the treatment of diabetes mellitus.
- In attempts to prepare pharmaceutical compositions of selected DPP-IV inhibitors it has been observed, that the DPP-IV inhibitors with a primary or secondary amino group show incompatibilities, degradation problems, or extraction problems with a number of customary excipients such as microcrystalline cellulose, sodium starch glycolate, croscarmellose sodium, tartaric acid, citric acid, glucose, fructose, saccharose, lactose, maltodextrines. Though the compounds themselves are very stable, they react with many excipients used in solid dosage forms and with impurities of excipients, especially in tight contact provided in tablets and at high excipient/drug ratios. The amino group appears to react with reducing sugars and with other reactive carbonyl groups and with carboxylic acid functional groups formed for example at the surface of microcrystalline cellulose by oxidation. These unforeseen difficulties are primarily observed in low dosage ranges which are required due to the surprising potency of the selected inhibitors. Thus, pharmaceutical compositions are required so solve these technical problems associated with the unexpected potency of selected DPP-IV inhibitor compounds.
- A pharmaceutical composition according to the present invention is intended for the treatment of to achieve glycemic control in a type 1 or type 2 diabetes mellitus patient and comprises a DPP-IV inhibitor with an amino group, especially a free or primary amino group, as an active ingredient, a first and second diluent, a binder, a disintegrant and a lubricant. An additional disintegrant and an additional glidant are a further option. Additionally the compositions can be used to treat rheumatoid arthritis, obesity and osteoporosis as well as to support allograft transplantation.
- Diluents suitable for a pharmaceutical composition according to the invention are cellulose powder, dibasic calciumphosphate anhydrous, dibasic calciumphosphate dihydrate, erythritol, low substituted hydroxypropyl cellulose, mannitol, pregelatinized starch or xylitol. Among those diluents mannitol and pregelatinized starch are preferred.
- Diluents preferred as the second diluent are the above mentioned diluents pre-gelatinized starch and low-substituted hydroxypropylcellulose (L-HPC) which show additional binder properties.
- Lubricants suitable for a pharmaceutical composition according to the invention are talc, polyethyleneglycol, calcium behenate, calcium stearate, hydrogenated castor oil or magnesium stearate. The preferred lubricant is magnesium stearate.
- Binders suitable for a pharmaceutical composition according to the invention are copovidone (copolymerisates of vinylpyrrolidon with other vinylderivates), hydroxypropyl methylcellulose (HPMC), hydroxypropylcellulose (HPC), polyvinylpyrrolidon (povidone), pregelatinized starch, low-substituted hydroxypropylcellulose (L-HPC), copovidone and pregelatinized starch being preferred.
- The above mentioned binders pregelatinized starch and L-HPC show additional diluent and disintegrant properties and can also be used as the second diluent or the disintegrant.
- Disintegrants suitable for a pharmaceutical composition according to the present invention are corn starch, crospovidone, low-substituted hydroxypropylcellulose (L-HPC) or pregelatinized starch, corn starch being preferred.
- As an optional glidant colloidal silicon dioxide can be used.
- An exemplary composition according to the present invention comprises the diluent mannitol, pregelatinized starch as a diluent with additional binder properties, the binder copovidone, the disintegrant corn starch, and magnesium stearate as the lubricant.
- Dosage forms prepared with a pharmaceutical compositions according to the present invention contain active ingredients in dosage ranges of 0.1-100 mg. Preferred dosages are 0.5 mg, 1 mg, 2.5 mg, 5 mg and 10 mg.
- Typical pharmaceutical compositions comprise (% by weight)
- 0.5-20% active ingredient
- 40-88% diluent 1,
- 3-40% diluent 2,
- 1-5% binder,
- 5-15% disintegrant, and
- 0.1-4% lubricant.
- Preferred pharmaceutical compositions comprise (% by weight)
- 0.5-7% active ingredient
- 50-75% diluent 1,
- 5-15% diluent 2,
- 2-4% binder,
- 8-12% disintegrant, and
- 0.5-2% lubricant
- The pharmaceutical compositions according to the invention are intended for oral use and can be used in the dosage form of a capsule, a tablet or a film-coated tablet. Typically the film coat represents 2-4%, preferably 3% of the composition and comprises a film-forming agent, a plasticizer, a glidant and optionally one or more pigments. An exemplary coat composition may comprise hydroxypropylmethylcellulose (HPMC), polyethylene glycol (PEG), talc, titanium dioxide and optionally iron oxide.
- Preferred active ingredients in the context of the present invention are DPP-IV inhibitors with a primary amino group and salts thereof such as any DPP-IV inhibitor and salt thereof defined by formula (I)
- or formula (II)
- wherein R1 is ([1,5]naphthyridin-2-yl)methyl, (quinazolin-2-yl)methyl], (quinoxalin-6-yl)methyl, (4-Methyl-quinazolin-2-yl)methyl, 2-Cyano-benzyl, (3-Cyano-quinolin-2-yl)methyl, (3-Cyano-pyridin-2-yl)methyl, (4-Methyl-pyrimidin-2-yl)methyl, or (4,6-Dimethyl-pyrimidin-2-yl)methyl, and R2 is 3-(R)-amino-piperidin-1-yl, (2-amino-2-methyl-propyl)-methylamino or (2-(S)-amino-propyl)-methylamino.
- Preferred DPP IV inhibitor compounds are the following compounds and salts thereof:
-
- 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine (compare WO 2004/018468, example 2(142):
-
- 1-[([1,5]naphthyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine (compare WO 2004/018468, example 2(252)):
-
- 1-[(Quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine (compare WO 2004/018468, example 2(80)):
-
- 2-((R)-3-Amino-piperidin-1-yl)-3-(but-2-yinyl)-5-(4-methyl-quinazolin-2-ylmethyl)-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one (compare WO 2004/050658, example 136):
-
- 1-[(4-Methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyin-1-yl)-8-[(2-amino-2-methyl-propyl)-methylamino]-xanthine (compare WO 2006/029769, example 2(1)):
-
- 1-[(3-Cyano-quinolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine (compare WO 2005/085246, example 1(30)):
-
- 1-(2-Cyano-benzyl)-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine (compare WO 2005/085246, example 1(39)):
-
- 1-[(4-Methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[(S)-(2-amino-propyl)-methylamino]-xanthine (compare WO 2006/029769, example 2(4)):
-
- 1-[(3-Cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine (compare WO 2005/085246, example 1(52)):
-
- 1-[(4-Methyl-pyrimidin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine (compare WO 2005/085246, example 1(81)):
-
- 1-[(4,6-Dimethyl-pyrimidin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine (compare WO 2005/085246, example 1(82)):
-
- 1-[(Quinoxalin-6-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine (compare WO 2005/085246, example 1(83)):
- To prepare compositions according to the invention a granulate can be prepared by a wet granulation process. Alternative methods for granulation of active ingredient and excipients with a granulation liquid are fluid bed granulation or one-pot granulation.
- In the wet granulation process the granulation liquid is a solvent such as water, ethanol, methanol, isopropanol, acetone, preferably purified water, and contains a binder such as copovidone. The solvent is a volatile component, which does not remain in the final product. The active ingredient and the other excipients with exception of the lubricant are premixed and granulated with the aqueous granulation liquid using a high shear granulator. The wet granulation step is followed by an optional wet sieving step, drying and dry sieving of the granules. For example a fluid bed dryer can then be used for drying.
- The dried granules are sieved through an appropriate sieve. After addition of the other excipients with exception of the lubricant the mixture is blended in a suitable conventional blender such as a free fall blender followed by addition of the lubricant such as magnesium stearate and final blending in the blender.
- Thus an exemplary wet granulation process for the preparation of a pharmaceutical composition according to the present invention comprises
- a. dissolving a binder such as copovidone in a solvent such as purified water at ambient temperature to produce a granulation liquid;
- b. blending a DPP-IV inhibitor, a diluent, and a disintegrant in a suitable mixer, to produce a pre-mix;
- c. moistening the pre-mix with the granulation liquid and subsequently granulating the moistened pre-mix for example in a high shear mixer;
- d. optionally sieving the granulated pre-mix through a sieve with a mesh size of at least 1.0 mm and preferably 3 mm;
- e. drying the granulate at about 40-75° C. and preferably 55-65° C. inlet air temperature for example in a fluid bed dryer until the desired loss on drying value in the range of 1-5% is obtained;
- f. delumping the dried granulate for example by sieving through a sieve with a mesh size of 0.6 mm-1.6 mm, preferably 1.0 mm; and
- g. adding preferably sieved lubricant to the granulate for final blending for example in a cube mixer.
- In an alternative process part of the excipients such as part of a disintegrant (e.g. corn starch) or a diluent (e.g. pregelatinized starch) or an additional disintegrant (crospovidone) can be added extragranular prior to final blending of step g.
- In another alternative version of the process the granulate produced in steps a to e is produced in a one pot high shear granulation process and subsequent drying in a one pot granulator.
- For the preparation of capsules the final blend is further filled into capsules.
- For the preparation of tablets or tablet cores the final blend is further compressed into tablets of the target tablet core weight with appropriate size and crushing strength, using an appropriate tablet press.
- For the preparation of film-coated tablets a coating suspension is prepared and the compressed tablet cores are coated with the coating suspension to a weight gain of about 2-4%, preferably about 3%, using a standard film coater. The film-coating solvent is a volatile component, which does not remain in the final product. To reduce the required amount of lubricant in the tablets it is an option to use an external lubrication system.
- An active DPP IV inhibitor ingredient with a primary amino group and all other excipients with exception of magnesium stearate are blended in a high shear blender. This pre-mix is sieved through a 1 mm sieve. After addition of magnesium stearate the pre-mix is blended in a free fall blender to produce the final blend. The final blend is compressed into tablets using a suitable tablet press. The following compositions can be obtained:
-
Component mg/tablet %/tablet mg/tablet %/tablet Active ingredient 1.000 2.000 2.500 2.000 Mannitol 43.250 86.500 108.125 86.500 Pregelatinized starch 5.000 10.000 12.500 10.000 Magnesium stearate 0.750 1.500 1.875 1.500 Total 50.000 100.000 125.000 100.000 -
Component mg/tablet %/tablet mg/tablet %/tablet Active ingredient 5.000 2.000 10.000 2.000 Mannitol 216.250 86.500 432.500 86.500 Pregelatinized starch 25.000 10.000 50.000 10.000 Magnesium stearate 3.750 1.500 7.500 1.500 Total 250.000 100.000 500.000 100.000 - An active DPP IV inhibitor ingredient with a primary amino group and all other excipients with exception of magnesium stearate are blended in a high shear blender. This pre-mix is sieved through a 1 mm sieve. After addition of magnesium stearate the pre-mix is blended in a free fall blender to produce the final blend. The final blend is compressed into tablets using a suitable tablet press. The following compositions can be obtained:
-
Component mg/tablet %/tablet mg/tablet %/tablet Active ingredient 1.000 1.667 0.500 0.833 Dibasic 46.400 77.333 46.900 78.177 calciumphosphate, anhydrous Low-substituted 12.000 20.000 12.000 20.000 hydroxypropylcellulose Magnesium stearate 0.600 1.000 0.600 1.000 Total 60.000 100.000 60.000 100.000 -
Component mg/tablet %/tablet mg/tablet %/tablet Active ingredient 10.000 1.667 10.000 2.222 Dibasic 464.000 77.333 344.000 76.788 calciumphosphate, anhydrous Low-substituted 120.000 20.000 90.000 20.000 hydroxypropylcellulose Magnesium stearate 6.000 1.000 6.000 1.000 Total 600.000 100.000 450.000 100.000 - Copovidone is dissolved in purified water at ambient temperature to produce a granulation liquid. An active DPP IV inhibitor ingredient with a primary amino group, mannitol and part of the pregelatinized starch are blended in a suitable mixer, to produce a pre-mix. The pre-mix is moistened with the granulation liquid and subsequently granulated. The moist granulate is optionally sieved through a sieve with a mesh size of 1.6-3.0 mm. The granulate is dried at 55° C. in a suitable dryer to a residual moisture content corresponding to 2-5% loss on drying. The dried granulate is sieved through a sieve with a mesh size of 1.0 mm. The granulate is blended with part of the pregelatinized starch in a suitable mixer. Magnesium stearate is added to this blend after passing through a 1.0 mm sieve for delumping. Subsequently the final blend is produced by final blending in a suitable mixer and compressed into tablets. The following tablet composition can be obtained:
-
Component mg/tablet %/tablet Active ingredient 10.000 1.667 Pregelatinized starch 210.000 35.000 Mannitol 236.000 39.333 Copovidone 18.000 3.000 Total (granulate) 474.000 79.000 Pregelatinized starch 120.000 20.000 Magnesium stearate 6.000 1.000 Total 600.000 100.000 - Copovidone is dissolved in purified water at ambient temperature to produce a granulation liquid. An active DPP IV inhibitor ingredient with a primary amino group, mannitol, pregelatinized starch and corn starch are blended in a suitable mixer to produce the pre-mix. The pre-mix is moistened with the granulation liquid and subsequently granulated using a high shear mixer. The moist granulate is optionally sieved through a sieve with a mesh size of 1.6-3.0 mm. The granulate is dried at about 60° C. in a fluid bed dryer until a loss on the drying value of 2-4% is obtained. The Final Blend is compressed into tablet cores.
- Hydroxypropyl methylcellulose, polyethylene glycol, talc, titanium dioxide and iron oxide are suspended in purified water in a suitable mixer at ambient temperature to produce a coating suspension. The tablet cores are coated with the coating suspension to a weight gain of about 3% to produce film-coated tablets. The following tablet compositions can be obtained:
-
Component mg mg mg mg mg Active ingredient 0.500 1.000 2.500 5.000 10.000 Mannitol 67.450 66.950 65.450 130.900 125.900 Pregelatinized starch 9.000 9.000 9.000 18.000 18.000 Corn starch 9.000 9.000 9.000 18.000 18.000 Copovidone 2.700 2.700 2.700 5.400 5.400 Magnesium stearate 1.350 1.350 1.350 2.700 2.700 Total Mass 90.000 90.000 90.000 180.000 180.000 (tablet core) HPMC 1.500 1.500 1.500 2.500 2.500 PEG 0.150 0.150 0.150 0.250 0.250 Titanium dioxide 0.750 0.750 0.750 1.250 1.250 Talc 0.525 0.525 0.525 0.875 0.875 Iron oxide, yellow 0.075 0.075 0.075 0.125 0.125 Total Mass 93.000 93.000 93.000 185.000 185.000 (coated tablet) - Copovidone is dissolved in purified water at ambient temperature to produce a granulation liquid. An active DPP IV inhibitor ingredient with a primary amino group, mannitol and pregelatinized starch are blended in a suitable mixer to produce a pre-mix. The pre-mix is moistened with the granulation liquid and subsequently granulated. The moist granulate is optionally sieved through a suitable sieve. The granulate is dried at about 50° C. in a suitable dryer until a loss on drying value of 3-5% is obtained. The dried granulate is sieved through a sieve with a mesh size of 1.0 mm.
- Magnesium stearate is passed through a 1.0 mm sieve and added to the granulate. Subsequently the final blend is produced by final blending in a suitable blender and the final blend is compressed into tablets. The following tablet compositions can be obtained:
-
Component mg mg mg mg mg Active ingredient 0.500 1.000 2.500 5.000 10.000 Mannitol 27.500 27.000 67.500 135.000 130.000 Pregelatinized starch 20.000 20.000 50.000 100.000 100.000 Copovidone 1.500 1.500 3.750 7.500 7.500 Magnesium stearate 0.500 0.500 1.250 2.500 2.500 Total tablet mass 50.000 50.000 125.000 250.000 250.000 - Copovidone is dissolved in purified water at ambient temperature to produce a granulation liquid. An active DPP IV inhibitor ingredient with a primary amino group and a part of mannitol, pregelatinized starch and corn starch are blended in a suitable mixer, to produce a pre-mix. The pre-mix is moistened with the granulation liquid and subsequently granulated. The moist granulate is sieved through a suitable sieve. The granulate is dried at about 60° C. inlet air temperature in a fluid bed dryer until a loss on drying value of 1-4% is obtained. The dried granulate is sieved through a sieve with a mesh size of 1.0 mm.
- Magnesium stearate is passed through a sieve for delumping and added to the granulate. Additionally the remaining part of the excipients are added extragranular at this process step. Subsequently the final blend is produced by final blending in a suitable blender and compressed into tablet cores.
- Hydroxypropyl methylcellulose, polyethylene glycol, talc, titanium dioxide and iron oxide are suspended in purified water in a suitable mixer at ambient temperature to produce a coating suspension. The tablet cores are coated with the coating suspension to a weight gain of about 3% to produce film-coated tablets. The following formulation variants can be obtained:
-
-
Formulation E Formulation F Component mg/Tablet %/Tablet mg/Tablet %/Tablet Active ingredient 1.000 1.111 1.000 1.111 Mannitol 23.300 25.889 66.950 74.389 Pregelatinized starch 4.500 5.000 4.500 5.000 Corn starch 4.500 5.000 4.500 5.000 Copovidone 1.350 1.500 2.700 3.000 Total (granulate) 34.650 38.500 79.650 88.500 Corn starch 4.500 5.000 4.500 5.000 Pregelatinized starch 4.500 5.000 4.500 5.000 Mannitol 45.000 50.000 Magnesium stearate 1.350 1.500 1.350 1.500 Total (tablet core) 90.000 100.000 90.000 100.000 -
-
Component mg mg mg mg mg Active ingredient 0.500 1.000 2.500 5.000 10.000 Mannitol 67.450 66.950 65.450 130.900 125.900 Pregelatinized starch 9.000 9.000 9.000 18.000 18.000 Corn starch 9.000 9.000 9.000 18.000 18.000 Copovidone 2.700 2.700 2.700 5.400 5.400 Total Mass 88.650 88.650 88.650 177.300 177.300 (granulate) Magnesium stearate 1.350 1.350 1.350 2.700 2.700 Crospovidone 2.000 2.000 2.000 4.000 4.000 Total Mass 92.000 92.000 92.000 184.000 184.000 (tablet core) HPMC 1.500 1.500 1.500 2.500 2.500 PEG 0.150 0.150 0.150 0.250 0.250 Titanium dioxide 0.750 0.750 0.750 1.250 1.250 Talc 0.525 0.525 0.525 0.875 0.875 Iron oxide, yellow 0.075 0.075 0.075 0.125 0.125 Total Mass 95.000 95.000 95.000 189.000 189.000 (coated tablet) -
-
Component mg/tablet %/tablet mg/tablet %/tablet Active ingredient 25.000 27.778 50.000 27.778 Mannitol 40.700 45.222 81.400 45.222 Pregelatinized starch 9.000 10.000 18.000 10.000 Corn starch 9.000 10.000 18.000 10.000 Copovidone 2.700 3.000 5.400 3.000 Total (granulate) 86.400 96.000 172.800 96.000 Crospovidone 2.700 3.000 5.400 3.000 Magnesium stearate 0.900 1.000 1.800 1.000 Total (tablet core) 90.000 100.000 180.000 100.000 Hydroxypropyl 1.500 1.667 2.500 1.389 methylcellulose Polyethylene glycol 0.150 0.167 0.250 0.139 Titanium dioxide 0.750 0.833 1.250 0.694 Talcum 0.525 0.583 0.875 0.486 Iron oxide yellow 0.075 0.083 0.125 0.069 Total (film-coated tablet) 93.000 103.333 185.000 102.778
Claims (18)
1. A pharmaceutical composition comprising as an active ingredient a DPP IV inhibitor compound of formula
in an amount of 0.5 mg, 1 mg, 2.5 mg, 5 mg or 10 mg, or a salt thereof, a first diluent, a second diluent, a binder, a disintegrant and a lubricant, wherein the first diluent is mannitol, the second diluent is pregelatinized starch, the binder is copovidone, the disintegrant is corn starch, and the lubricant is magnesium stearate; and wherein the DPP IV inhibitor compound is present in an amount 0.5-20% based on the total weight of DPP IV inhibitor compound, first diluent, second diluent, binder, disintegrant and lubricant.
2. The pharmaceutical composition of claim 1 further comprising an additional disintegrant.
3. The pharmaceutical composition of claim 2 , wherein the additional disintegrant is crospovidone.
4. The pharmaceutical composition of claim 1 further comprising a glidant.
5. The pharmaceutical composition of claim 4 , wherein the glidant is colloidal silicon dioxide.
6. The pharmaceutical composition of claim 1 comprising
40-88% diluent 1,
3-40% diluent 2,
1-5% binder,
5-15% disintegrant, and
0.1-4% lubricant
7. The pharmaceutical composition of claim 1 comprising
0.5-7% active ingredient
50-75% diluent 1,
5-15% diluent 2,
2-4% binder,
8-12% disintegrant, and
0.5-2% lubricant
8. The pharmaceutical composition according to claim 1 in the dosage form of a capsule, a tablet, or a film-coated tablet.
9. The pharmaceutical composition of claim 8 comprising 2-4% film coat.
10. The pharmaceutical composition of claim 9 , wherein the film coat comprises a film-forming agent, a plasticizer, a glidant and optionally one or more pigments.
11. The pharmaceutical composition of claim 10 , wherein the film coat comprises hydroxypropylmethylcellulose (HPMC), polyethylene glycol (PEG), talc, titanium dioxide and iron oxide.
12. The pharmaceutical composition according to claim 1 , wherein 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine is comprised in an amount of 5 mg.
13. The pharmaceutical composition according to claim 12 in the form of a capsule, a tablet, or a film-coated tablet.
14. The pharmaceutical composition of claim 12 , wherein the composition is in the form of a film-coated tablet, and wherein the film coat comprise 2-4% wt % based the weight of the uncoated tablet.
15. The pharmaceutical composition of claim 14 , wherein the film coat comprises a film-forming agent, a plasticizer, a glidant and optionally one or more pigments.
16. The pharmaceutical composition of claim 15 , wherein the film coat comprises hydroxypropylmethylcellulose (HPMC), polyethylene glycol (PEG), talc, titanium dioxide and iron oxide.
17. The pharmaceutical composition according to claim 12 , which is an oral dosage form in the form of a tablet.
18. The pharmaceutical composition according to claim 12 , which is an oral dosage form in form of a film-coated tablet.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/655,269 US20170312287A1 (en) | 2006-05-04 | 2017-07-20 | Dpp iv inhibitor formulations |
US16/357,357 US11033552B2 (en) | 2006-05-04 | 2019-03-19 | DPP IV inhibitor formulations |
US17/319,325 US20210260068A1 (en) | 2006-05-04 | 2021-05-13 | Dpp iv inhibitor formulations |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06009201 | 2006-05-04 | ||
EP06009201A EP1852108A1 (en) | 2006-05-04 | 2006-05-04 | DPP IV inhibitor formulations |
US11/744,701 US20080107731A1 (en) | 2006-05-04 | 2007-05-04 | Dpp iv inhibitor formulations |
US13/230,133 US20120003313A1 (en) | 2006-05-04 | 2011-09-12 | Dpp iv inhibitor formulations |
US13/467,505 US20120219622A1 (en) | 2006-05-04 | 2012-05-09 | Dpp iv inhibitor formulations |
US13/735,078 US20130122089A1 (en) | 2006-05-04 | 2013-01-07 | Dpp iv inhibitor formulations |
US14/877,019 US20160022687A1 (en) | 2006-05-04 | 2015-10-07 | Dpp iv inhibitor formulations |
US15/655,269 US20170312287A1 (en) | 2006-05-04 | 2017-07-20 | Dpp iv inhibitor formulations |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/877,019 Continuation US20160022687A1 (en) | 2006-05-04 | 2015-10-07 | Dpp iv inhibitor formulations |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/357,357 Continuation US11033552B2 (en) | 2006-05-04 | 2019-03-19 | DPP IV inhibitor formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
US20170312287A1 true US20170312287A1 (en) | 2017-11-02 |
Family
ID=36972901
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/744,701 Abandoned US20080107731A1 (en) | 2006-05-04 | 2007-05-04 | Dpp iv inhibitor formulations |
US13/230,133 Abandoned US20120003313A1 (en) | 2006-05-04 | 2011-09-12 | Dpp iv inhibitor formulations |
US13/467,505 Abandoned US20120219622A1 (en) | 2006-05-04 | 2012-05-09 | Dpp iv inhibitor formulations |
US13/735,078 Abandoned US20130122089A1 (en) | 2006-05-04 | 2013-01-07 | Dpp iv inhibitor formulations |
US14/877,019 Abandoned US20160022687A1 (en) | 2006-05-04 | 2015-10-07 | Dpp iv inhibitor formulations |
US15/655,269 Abandoned US20170312287A1 (en) | 2006-05-04 | 2017-07-20 | Dpp iv inhibitor formulations |
US16/357,357 Active US11033552B2 (en) | 2006-05-04 | 2019-03-19 | DPP IV inhibitor formulations |
US17/319,325 Pending US20210260068A1 (en) | 2006-05-04 | 2021-05-13 | Dpp iv inhibitor formulations |
Family Applications Before (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/744,701 Abandoned US20080107731A1 (en) | 2006-05-04 | 2007-05-04 | Dpp iv inhibitor formulations |
US13/230,133 Abandoned US20120003313A1 (en) | 2006-05-04 | 2011-09-12 | Dpp iv inhibitor formulations |
US13/467,505 Abandoned US20120219622A1 (en) | 2006-05-04 | 2012-05-09 | Dpp iv inhibitor formulations |
US13/735,078 Abandoned US20130122089A1 (en) | 2006-05-04 | 2013-01-07 | Dpp iv inhibitor formulations |
US14/877,019 Abandoned US20160022687A1 (en) | 2006-05-04 | 2015-10-07 | Dpp iv inhibitor formulations |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/357,357 Active US11033552B2 (en) | 2006-05-04 | 2019-03-19 | DPP IV inhibitor formulations |
US17/319,325 Pending US20210260068A1 (en) | 2006-05-04 | 2021-05-13 | Dpp iv inhibitor formulations |
Country Status (37)
Country | Link |
---|---|
US (8) | US20080107731A1 (en) |
EP (5) | EP1852108A1 (en) |
JP (7) | JP5478244B2 (en) |
KR (5) | KR102051281B1 (en) |
CN (2) | CN102526737B (en) |
AR (2) | AR060755A1 (en) |
AT (1) | ATE480228T1 (en) |
AU (1) | AU2007247193B2 (en) |
BR (2) | BRPI0722388B1 (en) |
CA (1) | CA2649922C (en) |
CL (2) | CL2012002522A1 (en) |
CY (2) | CY1111354T1 (en) |
DE (1) | DE602007009091D1 (en) |
DK (3) | DK2277509T5 (en) |
EA (2) | EA029890B1 (en) |
EC (1) | ECSP088800A (en) |
ES (3) | ES2527409T4 (en) |
HK (2) | HK1172549A1 (en) |
HR (2) | HRP20100507T1 (en) |
HU (1) | HUE025210T2 (en) |
IL (2) | IL195030A (en) |
ME (2) | ME01170B (en) |
MX (2) | MX2008013958A (en) |
MY (2) | MY146969A (en) |
NO (1) | NO343067B1 (en) |
NZ (3) | NZ613426A (en) |
PE (2) | PE20080698A1 (en) |
PL (3) | PL2283819T3 (en) |
PT (2) | PT2283819E (en) |
RS (2) | RS51466B (en) |
SG (1) | SG171649A1 (en) |
SI (2) | SI2023902T1 (en) |
TW (2) | TWI474843B (en) |
UA (1) | UA94942C2 (en) |
UY (1) | UY30319A1 (en) |
WO (1) | WO2007128724A1 (en) |
ZA (1) | ZA200808361B (en) |
Families Citing this family (112)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7495005B2 (en) * | 2002-08-22 | 2009-02-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, their preparation and their use in pharmaceutical compositions |
US7482337B2 (en) * | 2002-11-08 | 2009-01-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
US7439370B2 (en) | 2004-05-10 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides |
DE102004030502A1 (en) | 2004-06-24 | 2006-01-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Novel imidazoles and triazoles, their preparation and use as medicines |
DE102004054054A1 (en) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines |
US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
DE102005035891A1 (en) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8- (3-amino-piperidin-1-yl) -xanthines, their preparation and their use as pharmaceuticals |
EP1852108A1 (en) * | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
BRPI0711558A2 (en) | 2006-05-04 | 2011-11-08 | Boeringer Ingelheim Internat Gmbh | polymorphs |
PE20080251A1 (en) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | USES OF DPP IV INHIBITORS |
WO2007143705A2 (en) | 2006-06-06 | 2007-12-13 | Intra-Cellular Therapies, Inc. | Organic compounds |
JP2010500326A (en) | 2006-08-08 | 2010-01-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Pyrrolo [3,2-D] pyrimidine as a DPP-IV inhibitor for the treatment of diabetes |
EP2025674A1 (en) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs |
PE20090938A1 (en) | 2007-08-16 | 2009-08-08 | Boehringer Ingelheim Int | PHARMACEUTICAL COMPOSITION INCLUDING A BENZENE DERIVATIVE SUBSTITUTED WITH GLUCOPYRANOSIL |
WO2009073210A1 (en) | 2007-12-06 | 2009-06-11 | Intra-Cellular Therapies, Inc | Organic compounds |
AR071175A1 (en) * | 2008-04-03 | 2010-06-02 | Boehringer Ingelheim Int | PHARMACEUTICAL COMPOSITION THAT INCLUDES AN INHIBITOR OF DIPEPTIDIL-PEPTIDASA-4 (DPP4) AND A COMPARING PHARMACO |
UY32030A (en) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN" |
KR20190016601A (en) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | Treatment for diabetes in patients inappropriate for metformin therapy |
RU2011108420A (en) * | 2008-08-14 | 2012-09-20 | Киорин Фармасьютикал Ко., Лтд. (Jp) | STABILIZED PHARMACEUTICAL COMPOSITION |
AU2009281122C1 (en) | 2008-08-15 | 2016-04-21 | Boehringer Ingelheim International Gmbh | Purin derivatives for use in the treatment of fab-related diseases |
EP2344195A2 (en) | 2008-09-10 | 2011-07-20 | Boehringer Ingelheim International GmbH | Combination therapy for the treatment of diabetes and related conditions |
JP5694773B2 (en) * | 2008-09-30 | 2015-04-01 | テバ製薬株式会社 | COMPRESSION MOLDED PREPARATION AND METHOD |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
ES2580759T3 (en) | 2008-12-06 | 2016-08-26 | Intra-Cellular Therapies, Inc. | Organic compounds |
PE20120120A1 (en) | 2008-12-06 | 2012-03-03 | Intra Cellular Therapies Inc | DERIVATIVES OF 2H-PYRAZOLO [3,4-d] PYRIMIDINE-4,6 (5H, 7H) -DIONA, AS PDE1 INHIBITORS |
BRPI0922700A2 (en) | 2008-12-06 | 2015-08-11 | Intracellular Therapies Inc | Organic compounds |
JP2012512848A (en) | 2008-12-23 | 2012-06-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Salt forms of organic compounds |
US8404727B2 (en) | 2009-01-07 | 2013-03-26 | Glenmark Pharmaceuticals S.A. | Pharmaceutical composition that includes a dipeptidyl peptidase-IV inhibitor |
TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
AR075204A1 (en) | 2009-01-29 | 2011-03-16 | Boehringer Ingelheim Int | DPP-4 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, USEFUL TO TREAT METABOLIC DISEASES IN PEDIATRIC PATIENTS, PARTICULARLY MELLITUS DIABETES TYPE 2 |
JP2012517977A (en) * | 2009-02-13 | 2012-08-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | An anti-diabetic drug comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other anti-diabetic drugs |
ES2797503T3 (en) | 2009-02-13 | 2020-12-02 | Boehringer Ingelheim Int | Pharmaceutical composition comprising an SGLT2 inhibitor, a DPP-IV inhibitor and optionally an additional antidiabetic agent and their uses |
UY32427A (en) * | 2009-02-13 | 2010-09-30 | Boheringer Ingelheim Internat Gmbh | PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL FORM, PROCEDURE FOR PREPARATION, METHODS OF TREATMENT AND USES OF THE SAME |
DK3351240T3 (en) | 2009-05-19 | 2019-06-17 | Celgene Corp | FORMULATIONS OF 4-AMINO-2- (2,6-DIOXOPIPERIDIN-3-YL) ISOINDOLIN-1,3-DION |
ES2596202T3 (en) | 2009-09-30 | 2017-01-05 | Boehringer Ingelheim International Gmbh | Method for the preparation of a crystalline form of 1-chloro-4- (β-D-glucopyranos-1-yl) -2- [4 - ((S) -tetrahydrofuran-3-yloxy) -benzyl] -benzene |
KR101813025B1 (en) | 2009-09-30 | 2017-12-28 | 베링거 인겔하임 인터내셔날 게엠베하 | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives |
PT2482812T (en) | 2009-10-02 | 2023-01-24 | Boehringer Ingelheim Int | Therapeutic uses of pharmaceutical compositions |
US10610489B2 (en) | 2009-10-02 | 2020-04-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
KR20210033559A (en) | 2009-11-27 | 2021-03-26 | 베링거 인겔하임 인터내셔날 게엠베하 | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
CN102711761B (en) | 2009-12-18 | 2015-06-03 | 田边三菱制药株式会社 | Elution-stabilized preparation |
WO2011107494A1 (en) | 2010-03-03 | 2011-09-09 | Sanofi | Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof |
JP5031054B2 (en) * | 2010-03-18 | 2012-09-19 | 信越化学工業株式会社 | Low substituted hydroxypropyl cellulose and solid preparation containing the same |
EP2547339A1 (en) | 2010-03-18 | 2013-01-23 | Boehringer Ingelheim International GmbH | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
AU2011249771A1 (en) * | 2010-05-05 | 2012-11-01 | Boehringer Ingelheim International Gmbh | Pharmaceutical formulations comprising pioglitazone and linagliptin |
US9186392B2 (en) * | 2010-05-05 | 2015-11-17 | Boehringer Ingelheim International Gmbh | Combination therapy |
US9434730B2 (en) | 2010-05-31 | 2016-09-06 | Intra-Cellular Therapies, Inc. | PDE1 inhibitor compounds |
EP2590657A4 (en) | 2010-05-31 | 2014-02-12 | Intra Cellular Therapies Inc | Organic compounds |
WO2011157827A1 (en) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
CA2803504C (en) | 2010-06-24 | 2022-08-30 | Boehringer Ingelheim International Gmbh | A combination for diabetes therapy comprising linagliptin and a long-acting insulin |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
AR083878A1 (en) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | VASOPROTECTORA AND CARDIOPROTECTORA ANTIDIABETIC THERAPY, LINAGLIPTINA, TREATMENT METHOD |
AR085689A1 (en) | 2011-03-07 | 2013-10-23 | Boehringer Ingelheim Int | PHARMACEUTICAL COMPOSITIONS OF METFORMIN, LINAGLIPTINE AND AN SGLT-2 INHIBITOR |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
WO2012120054A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120052A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
EP2683704B1 (en) | 2011-03-08 | 2014-12-17 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120055A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
EA023330B1 (en) | 2011-05-10 | 2016-05-31 | Сандоз Аг | Polymorph of linagliptin benzoate |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
CA2841552C (en) | 2011-07-15 | 2020-06-23 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US20130172244A1 (en) | 2011-12-29 | 2013-07-04 | Thomas Klein | Subcutaneous therapeutic use of dpp-4 inhibitor |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
US9192617B2 (en) | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
WO2013171166A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis |
EP2849755A1 (en) | 2012-05-14 | 2015-03-25 | Boehringer Ingelheim International GmbH | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
JP6374862B2 (en) | 2012-05-24 | 2018-08-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Xanthine derivatives as DPP-4 inhibitors for use in the treatment of autoimmune diabetes, particularly LADA |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
WO2013174769A1 (en) | 2012-05-25 | 2013-11-28 | Boehringer Ingelheim International Gmbh | Use of keratinocytes as a biologically active substance in the treatment of wounds, such as diabetic wounds, optionally in combination with a dpp-4 inhibitor |
WO2013183784A1 (en) | 2012-06-05 | 2013-12-12 | Takeda Pharmaceutical Company Limited | Solid preparation |
ES2659563T3 (en) | 2012-08-13 | 2018-03-16 | Sandoz Ag | Stable pharmaceutical composition containing 8 - [(3R) -3-amino-1-piperidinyl] -7- (2-butin-1-yl) -3,7-dihydro-3-methyl-1 - [(4-methyl -2-quinazolinyl) methyl] -1H-purin-2,6-dione or a pharmaceutically acceptable salt thereof |
WO2014045266A1 (en) | 2012-09-24 | 2014-03-27 | Ulf Eriksson | Treatment of type 2 diabetes and related conditions |
WO2014051025A1 (en) * | 2012-09-27 | 2014-04-03 | 株式会社 三和化学研究所 | Anagliptin-containing solid preparation |
WO2014051024A1 (en) * | 2012-09-27 | 2014-04-03 | 株式会社 三和化学研究所 | Anagliptin-containing drug composition |
KR20150059720A (en) * | 2012-09-27 | 2015-06-02 | 가부시키가이샤산와카가쿠켄큐쇼 | Anagliptin-containing preparation |
IN2015DN03795A (en) | 2012-10-24 | 2015-10-02 | Inserm Inst Nat De La Santé Et De La Rech Médicale | |
WO2014065427A1 (en) * | 2012-10-26 | 2014-05-01 | 株式会社 三和化学研究所 | Anagliptin-containing solid pharmaceutical preparation |
WO2014080384A1 (en) | 2012-11-26 | 2014-05-30 | Ranbaxy Laboratories Limited | Pharmaceutical composition of linagliptin |
US20140303097A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
ES2702174T3 (en) | 2013-04-05 | 2019-02-27 | Boehringer Ingelheim Int | Therapeutic uses of empagliflozin |
US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
MX2021004308A (en) | 2013-04-18 | 2022-10-26 | Boehringer Ingelheim Int | Pharmaceutical composition, methods for treating and uses thereof. |
EP2848241A1 (en) | 2013-09-12 | 2015-03-18 | Sanovel Ilac Sanayi ve Ticaret A.S. | Effervescent formulations of linagliptin |
TR201310724A2 (en) | 2013-09-12 | 2015-03-23 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Pharmaceutical formulati̇ons of linagliptin |
EP2848242A1 (en) | 2013-09-12 | 2015-03-18 | Sanovel Ilac Sanayi ve Ticaret A.S. | Orally disintegrating formulations of Linagliptin |
WO2015110962A1 (en) | 2014-01-21 | 2015-07-30 | Wockhardt Limited | Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and linagliptin or salts thereof |
ES2950384T3 (en) | 2014-02-28 | 2023-10-09 | Boehringer Ingelheim Int | Medical use of a DPP-4 inhibitor |
US20150283248A1 (en) * | 2014-04-02 | 2015-10-08 | Aurobindo Pharma Ltd. | Pharmaceutical compositions of Linagliptin and process for preparation thereof |
US9546175B2 (en) | 2014-08-07 | 2017-01-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
CN105878349A (en) * | 2014-11-28 | 2016-08-24 | 于凯 | Composition for preventing and treating osteoporosis caused by diabetics |
EP3273981B1 (en) | 2015-03-24 | 2020-04-29 | INSERM - Institut National de la Santé et de la Recherche Médicale | Method and pharmaceutical composition for use in the treatment of diabetes |
EP3310357A1 (en) * | 2015-06-17 | 2018-04-25 | H e x a l Aktiengesellschaft | Alogliptin formulation |
EA037498B1 (en) * | 2015-10-09 | 2021-04-05 | Хексаль Аг | Pharmaceutical composition containing 8-[(3r)-3-amino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[4-methyl-2-quinazolinyl)methyl]-1h-purine-2,6-dione or a pharmaceutically acceptable salt thereof |
EP3156048A1 (en) | 2015-10-13 | 2017-04-19 | Galenicum Health S.L. | Stable pharmaceutical composition of linagliptin in the form of immediate release tablets |
US9727330B2 (en) * | 2015-11-25 | 2017-08-08 | Red Hat, Inc. | Source to image transformation pipeline for a platform-as-a-service system |
CN105853382B (en) * | 2016-05-19 | 2019-07-19 | 广州迈达康医药科技有限公司 | A kind of Li Gelieting oral disintegrating tablet and preparation method thereof |
CA3022202A1 (en) | 2016-06-10 | 2017-12-14 | Boehringer Ingelheim International Gmbh | Combinations of linagliptin and metformin |
CN106236754A (en) * | 2016-07-31 | 2016-12-21 | 合肥远志医药科技开发有限公司 | A kind of compositions comprising Li Gelieting active component and preparation method thereof |
CN106137991A (en) * | 2016-08-01 | 2016-11-23 | 合肥远志医药科技开发有限公司 | A kind of Li Gelieting sheet method of granulating |
EP3551202B1 (en) | 2016-12-06 | 2024-01-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of enhancing the potency of incretin-based drugs in subjects in need thereof |
WO2020009675A2 (en) * | 2018-06-01 | 2020-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Solid oral pharmaceutical compositions of linagliptin |
WO2021076066A1 (en) | 2019-10-14 | 2021-04-22 | Santa Farma İlaç Sanayi̇ A.Ş. | Oral formulations comprising sitagliptin hci monohydrate with improved pharmaceutical characteristics |
CN113423404B (en) * | 2019-12-02 | 2023-09-29 | 成都苑东生物制药股份有限公司 | Xanthine derivative pharmaceutical composition and preparation method thereof |
CN117858703A (en) | 2021-07-22 | 2024-04-09 | 新梅斯托克公司 | Method for preparing pharmaceutical composition comprising linagliptin and metformin hydrochloride |
KR20230126664A (en) | 2022-02-23 | 2023-08-30 | 주식회사 제뉴원사이언스 | Pharmaceutical combination of controlled drug delivery comprising linagliptin or a pharmaceutically acceptable salt thereof and metformin or a pharmaceutically acceptable salt thereof |
CN115227661B (en) * | 2022-09-22 | 2022-12-13 | 北京惠之衡生物科技有限公司 | Linagliptin tablet and preparation method thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030016657A1 (en) * | 2001-07-19 | 2003-01-23 | International Business Machines Corporation | Instant messaging with voice conversation feature |
US20040009751A1 (en) * | 2002-07-11 | 2004-01-15 | Oliver Michaelis | Interface selection in a wireless communication network |
Family Cites Families (470)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2056046A (en) * | 1933-05-19 | 1936-09-29 | Rhone Poulenc Sa | Manufacture of bases derived from benz-dioxane |
US2375138A (en) * | 1942-05-01 | 1945-05-01 | American Cyanamid Co | Alkamine esters of aryloxymethyl benzoic acid |
US2629736A (en) * | 1951-02-24 | 1953-02-24 | Searle & Co | Basically substituted n-alkyl derivatives of alpha, beta, beta-triarylpropionamides |
US2730544A (en) * | 1952-07-23 | 1956-01-10 | Sahyun Lab | Alkylaminoalkyl esters of hydroxycyclohexylbenzoic acid |
US2750387A (en) * | 1953-11-25 | 1956-06-12 | Searle & Co | Basically substituted derivatives of diarylaminobenzamides |
DE1211359B (en) * | 1955-11-29 | 1966-02-24 | Oreal | Oxidant-free cold dye for human hair |
US2928833A (en) * | 1959-03-03 | 1960-03-15 | S E Massengill Company | Theophylline derivatives |
US3174901A (en) * | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
US3454635A (en) * | 1965-07-27 | 1969-07-08 | Hoechst Ag | Benzenesulfonyl-ureas and process for their manufacture |
US3673241A (en) * | 1968-04-04 | 1972-06-27 | Ciba Geigy Corp | Substituted benzaldehyde guanylhydrazones |
ES385302A1 (en) | 1970-10-22 | 1973-04-16 | Miquel S A Lab | Procedure for the obtaining of trisused derivatives of etilendiamine. (Machine-translation by Google Translate, not legally binding) |
DE2205815A1 (en) | 1972-02-08 | 1973-08-16 | Hoechst Ag | N-(oxazolin-2-yl)-piperazine - with antitussive activity |
JPS5512435B2 (en) * | 1972-07-01 | 1980-04-02 | ||
US4005208A (en) * | 1975-05-16 | 1977-01-25 | Smithkline Corporation | N-Heterocyclic-9-xanthenylamines |
US4061753A (en) | 1976-02-06 | 1977-12-06 | Interx Research Corporation | Treating psoriasis with transient pro-drug forms of xanthine derivatives |
AU508480B2 (en) | 1977-04-13 | 1980-03-20 | Asahi Kasei Kogyo Kabushiki Kaisha | Microcrystalline cellulose excipient and pharmaceutical composition containing thesame |
DE2758025A1 (en) | 1977-12-24 | 1979-07-12 | Bayer Ag | Tri:hydroxy-piperidine derivs. - useful as glucosidase inhibitors for treating diabetes etc. and as animal feed additives |
NO154918C (en) | 1977-08-27 | 1987-01-14 | Bayer Ag | ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE DERIVATIVES OF 3,4,5-TRIHYDROXYPIPERIDINE. |
DE2929596A1 (en) | 1979-07-21 | 1981-02-05 | Hoechst Ag | METHOD FOR PRODUCING OXOALKYL XANTHINES |
CY1306A (en) | 1980-10-01 | 1985-12-06 | Glaxo Group Ltd | Aminoalkyl furan derivative |
US4382091A (en) | 1981-04-30 | 1983-05-03 | Syntex (U.S.A.) Inc. | Stabilization of 1-substituted imidazole derivatives in talc |
FR2558162B1 (en) * | 1984-01-17 | 1986-04-25 | Adir | NOVEL XANTHINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
FI79107C (en) * | 1984-06-25 | 1989-11-10 | Orion Yhtymae Oy | Process for the preparation of stable form of prazosin hydrochloride. |
JPS6130567A (en) | 1984-07-23 | 1986-02-12 | Shiseido Co Ltd | Method of stabilizing urea |
JPS61124383A (en) | 1984-11-16 | 1986-06-12 | Unitika Ltd | Stabilization of immobilized fibrinolytic enzyme |
AR240698A1 (en) * | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Process for the preparation of 5-(4-(2-(5-ethyl-2-pyridil)-ethoxy)benzyl)-2,4-thiazolodinedione and their salts |
CA1242699A (en) | 1985-02-01 | 1988-10-04 | Bristol-Myers Company | Cefbuperazone and derivatives thereof |
GB8515934D0 (en) * | 1985-06-24 | 1985-07-24 | Janssen Pharmaceutica Nv | (4-piperidinomethyl and-hetero)purines |
US5258380A (en) * | 1985-06-24 | 1993-11-02 | Janssen Pharmaceutica N.V. | (4-piperidinylmethyl and -hetero)purines |
DE3688827T2 (en) | 1985-10-25 | 1994-03-31 | Beecham Group Plc | Piperidine derivative, its manufacture and its use as a medicine. |
US5034225A (en) | 1985-12-17 | 1991-07-23 | Genentech Inc. | Stabilized human tissue plasminogen activator compositions |
US5433959A (en) | 1986-02-13 | 1995-07-18 | Takeda Chemical Industries, Ltd. | Stabilized pharmaceutical composition |
ATE72244T1 (en) | 1986-03-21 | 1992-02-15 | Heumann Pharma Gmbh & Co | CRYSTALLINE ANHYDROUS SIGMA FORM OF 2-(4-(2FUROYL-(2-PIPERAZINE)-1-YL>-4-AMINO-6,7-DIMETHOXYQUINAZOLINE HYDROCHLORIDE AND PROCESS FOR THEIR PREPARATION. |
US5120712A (en) | 1986-05-05 | 1992-06-09 | The General Hospital Corporation | Insulinotropic hormone |
ATE110083T1 (en) | 1986-05-05 | 1994-09-15 | Gen Hospital Corp | INSULINOTROPIC HORMONE. |
AU619444B2 (en) | 1986-06-02 | 1992-01-30 | Nippon Chemiphar Co. Ltd. | 2-(2-aminobenzylsulfinyl)- benzimidazole derivatives |
US4968672A (en) | 1987-01-02 | 1990-11-06 | The United States Of America As Represented By The Department Of Health And Human Services | Adenosine receptor prodrugs |
US4743450A (en) | 1987-02-24 | 1988-05-10 | Warner-Lambert Company | Stabilized compositions |
JPS6440433A (en) | 1987-08-05 | 1989-02-10 | Green Cross Corp | Aqueous liquid composition of thrombin |
EP0342675B1 (en) | 1988-05-19 | 1995-01-25 | Chugai Seiyaku Kabushiki Kaisha | Novel quinolonecarboxylic acid derivatives |
US5329025A (en) * | 1988-09-21 | 1994-07-12 | G. D. Searle & Co. | 3-azido compound |
US5234897A (en) * | 1989-03-15 | 1993-08-10 | Bayer Aktiengesellschaft | Herbicidal 3-amino-5-aminocarbonyl-1,2,4-triazoles |
DE3926119A1 (en) | 1989-08-08 | 1991-02-14 | Bayer Ag | 3-AMINO-5-AMINOCARBONYL-1,2,4-TRIAZOLE DERIVATIVES |
GB8906792D0 (en) | 1989-03-23 | 1989-05-10 | Beecham Wuelfing Gmbh & Co Kg | Treatment and compounds |
DE3916430A1 (en) * | 1989-05-20 | 1990-11-22 | Bayer Ag | METHOD FOR PRODUCING 3-AMINO-5-AMINOCARBONYL-1,2,4-TRIAZOLE DERIVATIVES |
IL94390A (en) | 1989-05-30 | 1996-03-31 | Merck & Co Inc | Di-substituted imidazo fused 6-membered nitrogen-containing heterocycles and pharmaceutical compositions containing them |
US5332744A (en) * | 1989-05-30 | 1994-07-26 | Merck & Co., Inc. | Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists |
US5223499A (en) * | 1989-05-30 | 1993-06-29 | Merck & Co., Inc. | 6-amino substituted imidazo[4,5-bipyridines as angiotensin II antagonists |
FI94339C (en) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Process for the preparation of pharmaceutically acceptable [R- (R *, R *)] - 2- (4-fluorophenyl) -, - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- for the preparation of pyrrole-1-heptanoic acid and its pharmaceutically acceptable salts |
HU208115B (en) | 1989-10-03 | 1993-08-30 | Biochemie Gmbh | New process for producting pleuromutilin derivatives |
FR2654935B1 (en) * | 1989-11-28 | 1994-07-01 | Lvmh Rech | USE OF XANTHINES, WHICH MAY BE INCORPORATED IN LIPOSOMES, TO PROMOTE PIGMENTATION OF THE SKIN OR HAIR. |
IL97219A (en) | 1990-02-19 | 1995-12-08 | Ciba Geigy Ag | Biphenyl substituted aliphatic amino compounds process for their preparation and pharmaceutical compositions containing them |
KR930000861B1 (en) | 1990-02-27 | 1993-02-08 | 한미약품공업 주식회사 | Omeprazole rectal composition |
ES2064887T3 (en) | 1990-09-13 | 1995-02-01 | Akzo Nobel Nv | STABILIZED SOLID CHEMICAL COMPOSITIONS. |
GB9020959D0 (en) | 1990-09-26 | 1990-11-07 | Beecham Group Plc | Novel compounds |
US5084460A (en) * | 1990-12-24 | 1992-01-28 | A. H. Robins Company, Incorporated | Methods of therapeutic treatment with N-(3-ouinuclidinyl)-2-hydroxybenzamides and thiobenzamides |
US5614519A (en) | 1991-02-06 | 1997-03-25 | Karl Thomae Gmbh | (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists |
US5602127A (en) | 1991-02-06 | 1997-02-11 | Karl Thomae Gmbh | (Alkanesultam-1-yl)-benzimidazol-1-yl)-1yl)-methyl-biphenyls useful as angiotensin-II antagonists |
US5594003A (en) | 1991-02-06 | 1997-01-14 | Dr. Karl Thomae Gmbh | Tetrahydroimidazo[1,2-a]pyridin-2-yl-(benzimidazol-1-yl)-methyl-biphenyls useful as angiotensin-II antagonists |
GB9109862D0 (en) | 1991-05-08 | 1991-07-03 | Beecham Lab Sa | Pharmaceutical formulations |
DE4124150A1 (en) | 1991-07-20 | 1993-01-21 | Bayer Ag | SUBSTITUTED TRIAZOLES |
US5300298A (en) * | 1992-05-06 | 1994-04-05 | The Pennsylvania Research Corporation | Methods of treating obesity with purine related compounds |
GB9215633D0 (en) | 1992-07-23 | 1992-09-09 | Smithkline Beecham Plc | Novel treatment |
ES2115725T3 (en) | 1992-07-31 | 1998-07-01 | Shionogi & Co | TRIAZOLYLTIOMETHYLETHEOPHALOSPORINE HYDROCHLORIDE, ITS CRYSTALLINE HYDRATE AND THE PREPARATION OF IT. |
TW252044B (en) | 1992-08-10 | 1995-07-21 | Boehringer Ingelheim Kg | |
US5358941A (en) | 1992-12-02 | 1994-10-25 | Merck & Co., Inc. | Dry mix formulation for bisphosphonic acids with lactose |
DE4242459A1 (en) * | 1992-12-16 | 1994-06-23 | Merck Patent Gmbh | imidazopyridines |
AU6087894A (en) | 1993-01-14 | 1994-08-15 | Cell Therapeutics, Inc. | Acetal or ketal substituted therapeutic compounds |
EP0638567A4 (en) | 1993-02-18 | 1995-05-10 | Kyowa Hakko Kogyo Kk | Adenosine incorporation inhibitor. |
JP3726291B2 (en) | 1993-07-05 | 2005-12-14 | 三菱ウェルファーマ株式会社 | Benzoxazine compound having stable crystal structure and process for producing the same |
FR2707641B1 (en) | 1993-07-16 | 1995-08-25 | Fournier Ind & Sante | Compounds of imidazol-5-carboxamide, their process for preparing their intermediates and their use in therapy. |
DE4339868A1 (en) | 1993-11-23 | 1995-05-24 | Merck Patent Gmbh | imidazopyridazines |
DE4404183A1 (en) | 1994-02-10 | 1995-08-17 | Merck Patent Gmbh | 4-amino-1-piperidylbenzoylguanidine |
US5545745A (en) | 1994-05-23 | 1996-08-13 | Sepracor, Inc. | Enantioselective preparation of optically pure albuterol |
CO4410191A1 (en) | 1994-09-19 | 1997-01-09 | Lilly Co Eli | SYNTHESIS OF 3- [4- (2-AMINOETOXI) BENZOIL] -2-ARYL-6- HYDROXYBENZO [b] THIOPHENES |
KR100237962B1 (en) | 1994-10-12 | 2000-02-01 | 그린 마틴 | Novel benzoxazoles |
GB9501178D0 (en) | 1995-01-20 | 1995-03-08 | Wellcome Found | Guanine derivative |
CA2218548A1 (en) | 1995-05-19 | 1996-11-21 | Chiroscience Limited | Xanthines and their therapeutic use |
JPH08333339A (en) | 1995-06-08 | 1996-12-17 | Fujisawa Pharmaceut Co Ltd | Production of optically active piperidineacetic acid derivative |
GB9523752D0 (en) | 1995-11-21 | 1996-01-24 | Pfizer Ltd | Pharmaceutical formulations |
DE19543478A1 (en) | 1995-11-22 | 1997-05-28 | Bayer Ag | Crystalline hydrochloride of {(R) - (-) - 2N- [4- (1,1-dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl) -buytl] aminomethyl} -chroman |
FR2742751B1 (en) | 1995-12-22 | 1998-01-30 | Rhone Poulenc Rorer Sa | NOVEL TAXOIDS, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
CA2241746A1 (en) | 1995-12-26 | 1997-07-03 | Alteon Inc. | N-acylaminoalkylhydrazinecarboximidamides |
US5891855A (en) | 1996-02-12 | 1999-04-06 | The Scripps Research Institute | Inhibitors of leaderless protein export |
DE19616486C5 (en) * | 1996-04-25 | 2016-06-30 | Royalty Pharma Collection Trust | Method for lowering the blood glucose level in mammals |
TWI240627B (en) | 1996-04-26 | 2005-10-01 | Chugai Pharmaceutical Co Ltd | Erythropoietin solution preparation |
US5965555A (en) | 1996-06-07 | 1999-10-12 | Hoechst Aktiengesellschaft | Xanthine compounds having terminally animated alkynol side chains |
WO1997046526A1 (en) | 1996-06-07 | 1997-12-11 | Eisai Co., Ltd. | Stable polymorphs of donepezil (1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine) hydrochloride and process for production |
US5958951A (en) | 1996-06-14 | 1999-09-28 | Novo Nordiskials | Modified form of the R(-)-N-(4,4-di(3-methylthien-2-yl)but-3-enyl)-nipecotic acid hydrochloride |
US5753635A (en) * | 1996-08-16 | 1998-05-19 | Berlex Laboratories, Inc. | Purine derivatives and their use as anti-coagulants |
NZ334346A (en) | 1996-09-23 | 2000-05-26 | Lilly Co Eli | Olanzapine dihydrate D comprising 2-methyl-4-(4-methyl-1-piperazinyl)-1OH-thieno[2,3-b][1,5]benzodiazepine and a formulation for use in treating central nervous system disorders |
JP2001502703A (en) | 1996-10-28 | 2001-02-27 | ノボ ノルディスク アクティーゼルスカブ | Method for preparing (-)-3,4-trans-diarylchroman |
UA65549C2 (en) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Use of glucagon-like peptides such as glp-1, glp-1 analog, or glp-1 derivative in methods and compositions for reducing body weight |
ATE366584T1 (en) | 1996-11-12 | 2007-08-15 | Novo Nordisk As | USE OF GLP-1 PEPTIDES |
GB9623859D0 (en) | 1996-11-15 | 1997-01-08 | Chiroscience Ltd | Novel compounds |
AU738362B2 (en) | 1996-12-24 | 2001-09-13 | Biogen Ma Inc. | Stable liquid interferon formulations |
DE19705233A1 (en) | 1997-02-12 | 1998-08-13 | Froelich Juergen C | Preparation of stable, orally administered arginine solutions |
US6011049A (en) | 1997-02-19 | 2000-01-04 | Warner-Lambert Company | Combinations for diabetes |
ES2167891T5 (en) | 1997-03-13 | 2005-11-16 | Hexal Ag | STABILIZATION OF SENSITIVE BENCIMIDAZOLS TO ACIDS WITH AMINO / CYCLODEXTRINE COMBINATIONS. |
US5972332A (en) | 1997-04-16 | 1999-10-26 | The Regents Of The University Of Michigan | Wound treatment with keratinocytes on a solid support enclosed in a porous material |
PE79099A1 (en) | 1997-06-13 | 1999-08-24 | Lilly Co Eli | STABLE INSULIN FORMULATIONS |
US6174548B1 (en) | 1998-08-28 | 2001-01-16 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
BR9813373A (en) | 1997-12-05 | 2000-10-03 | Astrazeneca Uk Ltd | Compound, process for preparing it, pharmaceutical composition, process for preparing it, use of a compound, and, processes for effecting immunosuppression and for treating or reducing the risk of reversibly obstructive airway disease in a patient |
TW589174B (en) | 1997-12-10 | 2004-06-01 | Takeda Chemical Industries Ltd | Agent for treating high-risk impaired glucose tolerance |
JPH11193270A (en) | 1997-12-26 | 1999-07-21 | Koei Chem Co Ltd | Production of optically active 1-methyl-3-piperidinemethanol |
CA2315736A1 (en) | 1998-01-05 | 1999-07-15 | Eisai Co., Ltd. | Purine compounds and adenosine a2 receptor antagonist as preventive or therapeutic for diabetes mellitus |
US6803357B1 (en) | 1998-02-02 | 2004-10-12 | New England Medical Center Hospitals, Inc. | Method of regulating glucose metabolism, and reagents related thereto |
US20030013740A1 (en) | 1998-03-27 | 2003-01-16 | Martin P. Redmon | Stable dosage forms of fluoxetine and its enantiomers |
EP1066265A1 (en) | 1998-03-31 | 2001-01-10 | Nissan Chemical Industries, Ltd. | Pyridazinone hydrochloride compound and method for producing the same |
EP0950658A1 (en) | 1998-04-13 | 1999-10-20 | Takeda Chemical Industries, Ltd. | 2-Pipirazinone-1-acetic acid dihydrochloride derivative used to inhibit platelet aggregation |
US6207207B1 (en) | 1998-05-01 | 2001-03-27 | Mars, Incorporated | Coated confectionery having a crispy starch based center and method of preparation |
DE19823831A1 (en) * | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | New pharmaceutical use of isoleucyl thiazolidide and its salts |
DE19828113A1 (en) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs of Dipeptidyl Peptidase IV Inhibitors |
DE19828114A1 (en) | 1998-06-24 | 2000-01-27 | Probiodrug Ges Fuer Arzneim | Produgs of unstable inhibitors of dipeptidyl peptidase IV |
AU743109B2 (en) | 1998-07-15 | 2002-01-17 | Asahi Kasei Kabushiki Kaisha | Excipient |
CO5150173A1 (en) | 1998-12-10 | 2002-04-29 | Novartis Ag | COMPOUNDS N- (REPLACED GLYCLE) -2-DIPEPTIDYL-IV PEPTIDASE INHIBITING CYANOPIRROLIDINS (DPP-IV) WHICH ARE EFFECTIVE IN THE TREATMENT OF CONDITIONS MEDIATED BY DPP-IV INHIBITION |
IT1312018B1 (en) | 1999-03-19 | 2002-04-04 | Fassi Aldo | IMPROVED PROCEDURE FOR THE PRODUCTION OF NON HYGROSCOPICIDAL SALTS OF L (-) - CARNITINE. |
WO2000066101A2 (en) | 1999-04-30 | 2000-11-09 | City Of Hope | Method of inhibiting glycation product formation |
US20040152659A1 (en) | 1999-05-12 | 2004-08-05 | Fujisawa Pharmaceutical Co. Ltd. | Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist |
WO2000069464A1 (en) | 1999-05-12 | 2000-11-23 | Fujisawa Pharmaceutical Co., Ltd. | Novel use |
WO2000072799A2 (en) | 1999-05-27 | 2000-12-07 | The University Of Virginia Patent Foundation | Method and compositions for treating the inflammatory response |
KR100767473B1 (en) | 1999-05-31 | 2007-10-17 | 미쯔비시 가가꾸 가부시끼가이샤 | Freeze Dried HGF Preparations |
EP1185371B2 (en) | 1999-06-01 | 2008-11-12 | Elan Pharma International Limited | Small-scale mill and method thereof |
US6545002B1 (en) | 1999-06-01 | 2003-04-08 | University Of Virginia Patent Foundation | Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors |
DK1731511T3 (en) * | 1999-06-21 | 2015-10-26 | Boehringer Ingelheim Pharma | Bicyclic heterocyclic structures, pharmaceutical compositions containing these compounds, their use and process for their preparation |
US6448323B1 (en) | 1999-07-09 | 2002-09-10 | Bpsi Holdings, Inc. | Film coatings and film coating compositions based on polyvinyl alcohol |
ES2166270B1 (en) | 1999-07-27 | 2003-04-01 | Almirall Prodesfarma Sa | DERIVATIVES OF 8-PHENYL-6,9-DIHIDRO- (1,2,4,) TRIAZOLO (3,4-I) PURIN-5-ONA. |
US6515117B2 (en) | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
US6586438B2 (en) | 1999-11-03 | 2003-07-01 | Bristol-Myers Squibb Co. | Antidiabetic formulation and method |
GB9928330D0 (en) | 1999-11-30 | 2000-01-26 | Ferring Bv | Novel antidiabetic agents |
CA2393083C (en) | 1999-12-23 | 2010-01-26 | Novartis Ag | Use of hypoglycemic agent for treating impaired glucose metabolism |
MXPA02006660A (en) | 2000-01-07 | 2002-12-13 | Transform Pharmaceuticals Inc | Highthroughput formation, identification, and analysis of diverse solidforms. |
US6362172B2 (en) | 2000-01-20 | 2002-03-26 | Bristol-Myers Squibb Company | Water soluble prodrugs of azole compounds |
EP1248604B2 (en) | 2000-01-21 | 2012-02-29 | Novartis AG | Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents |
JP4621326B2 (en) * | 2000-02-01 | 2011-01-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Teprenone stabilized composition |
WO2001056993A2 (en) * | 2000-02-05 | 2001-08-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compositions useful as inhibitors of erk |
CA2401356A1 (en) | 2000-02-24 | 2001-08-30 | Takeda Chemical Industries, Ltd. | Combination drug |
EP1132389A1 (en) | 2000-03-06 | 2001-09-12 | Vernalis Research Limited | New aza-indolyl derivatives for the treatment of obesity |
US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
GB0006133D0 (en) | 2000-03-14 | 2000-05-03 | Smithkline Beecham Plc | Novel pharmaceutical |
JP2001278812A (en) * | 2000-03-27 | 2001-10-10 | Kyoto Pharmaceutical Industries Ltd | Disintegrant for tablet and tablet using the same |
US6399101B1 (en) | 2000-03-30 | 2002-06-04 | Mova Pharmaceutical Corp. | Stable thyroid hormone preparations and method of making same |
ES2320630T5 (en) | 2000-03-31 | 2013-03-12 | Royalty Pharma Collection Trust | Method for the improvement of islet signaling in diabetes mellitus and for its prevention |
EP1273306A4 (en) | 2000-03-31 | 2005-06-22 | Kirin Brewery | Powdery preparation for transmucosal administration containing a polymeric form of drug and exhibiting improved storage stability |
JP2001292388A (en) | 2000-04-05 | 2001-10-19 | Sharp Corp | Reproducing device |
GB0008694D0 (en) | 2000-04-07 | 2000-05-31 | Novartis Ag | Organic compounds |
EP1295873A4 (en) | 2000-06-14 | 2004-05-19 | Processes for producing racemic piperidine derivative and for producing optically active piperidine derivative | |
GB0014969D0 (en) | 2000-06-19 | 2000-08-09 | Smithkline Beecham Plc | Novel method of treatment |
US7078397B2 (en) | 2000-06-19 | 2006-07-18 | Smithkline Beecham Corporation | Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus |
US6689353B1 (en) | 2000-06-28 | 2004-02-10 | Bayer Pharmaceuticals Corporation | Stabilized interleukin 2 |
HUP0301622A3 (en) * | 2000-07-04 | 2006-05-29 | Novo Nordisk As | Purine derivatives inhibiting the enzyme dipeptidyl petidase iv (dpp-iv) and pharmaceutical compositions containing them |
US7074794B2 (en) * | 2000-08-10 | 2006-07-11 | Mitsubishi Pharma Corporation | Proline derivatives and the use thereof as drugs |
US6821978B2 (en) | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
US20060034922A1 (en) | 2000-11-03 | 2006-02-16 | Andrx Labs, Llc | Controlled release metformin compositions |
US6722883B2 (en) | 2000-11-13 | 2004-04-20 | G & H Technologies Llc | Protective coating for abrasive dental tools and burs |
US6821261B2 (en) | 2000-12-12 | 2004-11-23 | Dj Orthopedics, Llc | Orthopedic brace having length-adjustable supports |
US20040180925A1 (en) | 2000-12-27 | 2004-09-16 | Kenji Matsuno | Dipeptidylpeptidase-IV inhibitor |
FR2818906B1 (en) | 2000-12-29 | 2004-04-02 | Dospharma | DRUG ASSOCIATION OF A BIGUANINE AND A CARRIER, FOR EXAMPLE OF METFORMIN AND ARGININE |
FR2819254B1 (en) | 2001-01-08 | 2003-04-18 | Fournier Lab Sa | NOVEL N- (PHENYLSULFONYL) GLYCINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE FOR OBTAINING PHARMACEUTICAL COMPOSITIONS |
DE10109021A1 (en) | 2001-02-24 | 2002-09-05 | Boehringer Ingelheim Pharma | New 8-substituted-xanthine derivatives, useful e.g. for treating diabetes and arthritis, act by inhibiting dipeptidylpeptidase-IV |
DE10117803A1 (en) | 2001-04-10 | 2002-10-24 | Boehringer Ingelheim Pharma | New 8-substituted-xanthine derivatives, useful e.g. for treating diabetes and arthritis, act by inhibiting dipeptidylpeptidase-IV |
PL364221A1 (en) | 2001-02-02 | 2004-12-13 | Takeda Chemical Industries, Ltd. | Fused heterocyclic compounds |
US6610326B2 (en) | 2001-02-16 | 2003-08-26 | Andrx Corporation | Divalproex sodium tablets |
US6649187B2 (en) | 2001-02-16 | 2003-11-18 | Bristol-Myers Squibb Pharma Company | Use of polyalkylamine polymers in controlled release devices |
PT1757606E (en) * | 2001-02-24 | 2009-05-26 | Boehringer Ingelheim Pharma | Xanthinderivatives for use as medical agents and the preparation thereof |
US6936590B2 (en) | 2001-03-13 | 2005-08-30 | Bristol Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
US6693094B2 (en) | 2001-03-22 | 2004-02-17 | Chrono Rx Llc | Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus |
JP2002348279A (en) | 2001-05-25 | 2002-12-04 | Nippon Kayaku Co Ltd | Production method for optically active pyridylketone derivatives and optically active pyridylketone derivatives |
DE10130371A1 (en) | 2001-06-23 | 2003-01-02 | Boehringer Ingelheim Pharma | New drug compositions based on anticholinergics, corticosteroids and betamimetics |
GB0115517D0 (en) | 2001-06-25 | 2001-08-15 | Ferring Bv | Novel antidiabetic agents |
US7183290B2 (en) | 2001-06-27 | 2007-02-27 | Smithkline Beecham Corporation | Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
CN1990468A (en) | 2001-06-27 | 2007-07-04 | 史密丝克莱恩比彻姆公司 | Pyrrolidines as dipeptidyl peptidase inhibitors |
US6869947B2 (en) * | 2001-07-03 | 2005-03-22 | Novo Nordisk A/S | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
ATE388951T1 (en) | 2001-07-03 | 2008-03-15 | Novo Nordisk As | DPP-IV INHIBITING PURINE DERIVATIVES FOR THE TREATMENT OF DIABETES |
UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
MXPA04000224A (en) | 2001-07-10 | 2005-07-25 | 4Sc Ag | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents. |
US7638522B2 (en) | 2001-08-13 | 2009-12-29 | Janssen Pharmaceutica N.V. | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile |
AR035119A1 (en) | 2001-08-16 | 2004-04-14 | Lilly Co Eli | ANTI-HTNFSF13B HUMAN ANTI-BODIES |
KR20040033048A (en) | 2001-09-14 | 2004-04-17 | 미츠비시 웰파마 가부시키가이샤 | Thiazolidine derivative and medicinal use thereof |
AU2002331311A1 (en) | 2001-09-19 | 2003-04-01 | Novo Nordisk A/S | Heterocyclic compounds that are inhibitors of the enzyme dpp-iv |
IL161335A0 (en) | 2001-10-15 | 2004-09-27 | Hemoteq Gmbh | Coating of stents for preventing restenosis |
DE10151296A1 (en) | 2001-10-17 | 2003-04-30 | Boehringer Ingelheim Pharma | Keratinocytes useful as a biologically active substance in the treatment of wounds |
US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
US20030083354A1 (en) | 2001-10-26 | 2003-05-01 | Pediamed Pharmaceuticals, Inc. | Phenylephrine tannate and pyrilamine tannate salts in pharmaceutical compositions |
US6861440B2 (en) | 2001-10-26 | 2005-03-01 | Hoffmann-La Roche Inc. | DPP IV inhibitors |
CA2363053C (en) | 2001-11-09 | 2011-01-25 | Bernard Charles Sherman | Clopidogrel bisulfate tablet formulation |
KR20040064687A (en) | 2001-12-21 | 2004-07-19 | 도오레 화인케미칼 가부시키가이샤 | Process for production of optically active cis-piperidine derivatives |
US6727261B2 (en) | 2001-12-27 | 2004-04-27 | Hoffman-La Roche Inc. | Pyrido[2,1-A]Isoquinoline derivatives |
WO2003057245A1 (en) | 2001-12-28 | 2003-07-17 | Nrl Pharma, Inc. | Compositions for improving lipid metabolism |
US20070197552A1 (en) | 2002-01-11 | 2007-08-23 | Novo Nordisk A/S | Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states |
ATE409466T1 (en) * | 2002-01-11 | 2008-10-15 | Novo Nordisk As | METHOD AND COMPOSITION FOR TREATING DIABETES, HYPERTENSION, CHRONIC HEART FAILURE AND CONDITIONS ASSOCIATED WITH FLUID RETENTION |
WO2003059327A1 (en) | 2002-01-16 | 2003-07-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof |
US8399414B2 (en) | 2002-01-21 | 2013-03-19 | Nrl Pharma, Inc. | Analgesics |
EP1333033A1 (en) | 2002-01-30 | 2003-08-06 | Boehringer Ingelheim Pharma GmbH & Co.KG | FAP-activated anti-tumor compounds |
CN1688291A (en) * | 2002-02-01 | 2005-10-26 | 辉瑞产品公司 | Immediate release dosage forms containing solid drug dispersions |
US7610153B2 (en) | 2002-02-13 | 2009-10-27 | Virginia Commonwealth University | Multi-drug titration and evaluation |
CA2476201C (en) | 2002-02-21 | 2009-09-01 | Biovail Laboratories Incorporated | Modified release formulations of at least one form of tramadol |
EP1338595B1 (en) | 2002-02-25 | 2006-05-03 | Eisai Co., Ltd. | Xanthine derivatives as DPP-IV inhibitors |
HUP0200849A2 (en) | 2002-03-06 | 2004-08-30 | Sanofi-Synthelabo | N-aminoacetyl-pyrrolidine-2-carbonitrile derivatives, pharmaceutical compositions containing them and process for producing them |
JP4298212B2 (en) | 2002-03-29 | 2009-07-15 | 大日本印刷株式会社 | Method for producing high melting point type epinastine hydrochloride |
JP2003300977A (en) | 2002-04-10 | 2003-10-21 | Sumitomo Pharmaceut Co Ltd | Xanthine derivative |
US20050113577A1 (en) | 2002-04-16 | 2005-05-26 | Karki Shyam B. | Solid forms of slats with tyrosine kinase activity |
CA2484306A1 (en) | 2002-04-26 | 2003-11-06 | Katsumi Maezono | Prophylactic and therapeutic agent of diabetes mellitus |
AU2003231252A1 (en) | 2002-05-09 | 2003-11-11 | Enos Pharmaceuticals, Inc. | Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease |
GB0212412D0 (en) | 2002-05-29 | 2002-07-10 | Novartis Ag | Combination of organic compounds |
MXPA04011862A (en) * | 2002-05-31 | 2005-03-31 | Schering Corp | Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof. |
BR0311697A (en) * | 2002-06-06 | 2005-03-22 | Eisai Co Ltd | New Condensed Imidazole Derivatives |
ES2199061B1 (en) * | 2002-06-10 | 2005-02-16 | Laboratorios Vita, S.A. | TROUBLE-BASED TABLETS AND PROCEDURE FOR OBTAINING. |
FR2840897B1 (en) | 2002-06-14 | 2004-09-10 | Fournier Lab Sa | NOVEL ARYLSULFONAMIDE DERIVATIVES AND THEIR USE IN THERAPEUTICS |
US20040002615A1 (en) | 2002-06-28 | 2004-01-01 | Allen David Robert | Preparation of chiral amino-nitriles |
US20040023981A1 (en) | 2002-07-24 | 2004-02-05 | Yu Ren | Salt forms with tyrosine kinase activity |
TW200409746A (en) | 2002-07-26 | 2004-06-16 | Theravance Inc | Crystalline β2 adrenergic receptor agonist |
TW200404796A (en) | 2002-08-19 | 2004-04-01 | Ono Pharmaceutical Co | Nitrogen-containing compound |
DE10238243A1 (en) | 2002-08-21 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New 8-(3-amino-piperidin-1-yl)-xanthine derivatives are dipeptidylpeptidase-IV inhibitors useful for, e.g. treating diabetes mellitus, arthritis or obesity |
ME00396B (en) * | 2002-08-21 | 2011-05-10 | Boehringer Ingelheim Pharma | 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
DE10238477A1 (en) | 2002-08-22 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New purine derivatives, their production and their use as medicines |
DE10238470A1 (en) | 2002-08-22 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New xanthine derivatives, their production and their use as medicines |
US7569574B2 (en) * | 2002-08-22 | 2009-08-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Purine derivatives, the preparation thereof and their use as pharmaceutical compositions |
US7495005B2 (en) * | 2002-08-22 | 2009-02-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, their preparation and their use in pharmaceutical compositions |
DE10238724A1 (en) | 2002-08-23 | 2004-03-04 | Bayer Ag | New 6-alkyl-1,5-dihydro-4H-pyrazolo-(3,4-d)-pyrimidin-4-ones useful as selective phosphodiesterase 9A inhibitors for improving attention, concentration, learning and/or memory performance |
DE10238723A1 (en) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl substituted pyrazolyprimidines |
JP2004123738A (en) * | 2002-09-11 | 2004-04-22 | Takeda Chem Ind Ltd | Sustained-release preparation |
US20060039974A1 (en) * | 2002-09-11 | 2006-02-23 | Takeda Pharmaceutical Company Limited | Sustained release preparation |
CN1688293A (en) * | 2002-09-16 | 2005-10-26 | 韦思公司 | Delayed release formulations for oral administration of a polypeptide therapeutic agent and methods of using same |
AU2003266559B2 (en) * | 2002-09-26 | 2008-01-24 | Eisai R&D Management Co., Ltd. | Combination drug |
CN1720025A (en) * | 2002-10-08 | 2006-01-11 | 兰贝克赛实验室有限公司 | Gabapentin tablets and methods for their preparation |
WO2004033455A2 (en) | 2002-10-08 | 2004-04-22 | Novo Nordisk A/S | Hemisuccinate salts of heterocyclic dpp-iv inhibitors |
US20040122048A1 (en) | 2002-10-11 | 2004-06-24 | Wyeth Holdings Corporation | Stabilized pharmaceutical composition containing basic excipients |
US6861526B2 (en) | 2002-10-16 | 2005-03-01 | Pfizer Inc. | Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine |
RU2301803C2 (en) | 2002-10-18 | 2007-06-27 | Мерк Энд Ко., Инк. | Derivatives of hexahydrodiazepinone, pharmaceutical composition containing thereof and using in preparing medicinal agent for treatment of non-insulin dependent diabetes mellitus |
JP2004161749A (en) | 2002-10-24 | 2004-06-10 | Toray Fine Chemicals Co Ltd | Method for producing optically active, nitrogen-containing compound |
AU2003280680A1 (en) | 2002-11-01 | 2004-06-18 | Sumitomo Pharmaceuticals Co., Ltd. | Xanthine compound |
AU2003290577B2 (en) | 2002-11-07 | 2008-12-11 | Merck Sharp & Dohme Corp. | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
US7482337B2 (en) | 2002-11-08 | 2009-01-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
DE10251927A1 (en) | 2002-11-08 | 2004-05-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New 1,7,8-trisubstituted xanthine derivatives, are dipeptidylpeptidase-IV inhibitors useful e.g. for treating diabetes mellitus type I or II, arthritis or obesity |
DE10254304A1 (en) * | 2002-11-21 | 2004-06-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New xanthine derivatives, their production and their use as medicines |
UY28103A1 (en) | 2002-12-03 | 2004-06-30 | Boehringer Ingelheim Pharma | NEW IMIDAZO-PIRIDINONAS REPLACED, ITS PREPARATION AND ITS EMPLOYMENT AS MEDICATIONS |
US7109192B2 (en) * | 2002-12-03 | 2006-09-19 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions |
ATE404191T1 (en) | 2002-12-10 | 2008-08-15 | Novartis Pharma Ag | COMBINATIONS OF A DPP-IV INHIBITOR AND A PPAR-ALPHA AGONIST |
US20040152720A1 (en) | 2002-12-20 | 2004-08-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Powdered medicaments containing a tiotropium salt and salmeterol xinafoate |
DE10351663A1 (en) | 2002-12-20 | 2004-07-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Stable, accurately dosable inhalable powder medicament for treating asthma or chronic obstructive pulmonary disease, containing tiotropium, specific form of salmeterol xinafoate and auxiliary |
DK1599222T3 (en) | 2003-01-08 | 2009-04-27 | Novartis Vaccines & Diagnostic | Stabilized aqueous preparations comprising v vs factor pathway inhibitor (TFPI) or v vs factor pathway inhibitor variant |
AU2004205642C1 (en) | 2003-01-14 | 2012-01-12 | Arena Pharmaceuticals, Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
DE10335027A1 (en) | 2003-07-31 | 2005-02-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of telmisartan and simvastatin for treatment or prophylaxis of cardiovascular, cardiopulmonary and renal diseases e.g. hypertension combined with hyperlipidemia or atherosclerosis |
PE20040950A1 (en) | 2003-02-14 | 2005-01-01 | Theravance Inc | BIPHENYL DERIVATIVES AS AGONISTS OF ß2-ADRENERGIC RECEPTORS AND AS ANTAGONISTS OF MUSCARINAL RECEPTORS |
JP2004250336A (en) * | 2003-02-18 | 2004-09-09 | Kao Corp | Method for producing coated tablet and sugar-coated tablet |
US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
US7442387B2 (en) | 2003-03-06 | 2008-10-28 | Astellas Pharma Inc. | Pharmaceutical composition for controlled release of active substances and manufacturing method thereof |
JP2006519852A (en) | 2003-03-12 | 2006-08-31 | アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ | Weak base salt |
BRPI0408490A (en) | 2003-03-18 | 2006-04-04 | Novartis Ag | compositions comprising fatty acids and amino acids |
DK2368553T3 (en) | 2003-04-08 | 2015-02-09 | Progenics Pharm Inc | Pharmaceutical preparation comprising methylnaltrexone |
US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
WO2004096806A1 (en) | 2003-04-30 | 2004-11-11 | Sumitomo Pharmaceuticals Co. Ltd. | Fused imidazole derivative |
TW200510277A (en) | 2003-05-27 | 2005-03-16 | Theravance Inc | Crystalline form of β2-adrenergic receptor agonist |
FR2855521B1 (en) | 2003-05-28 | 2005-08-05 | Flamel Tech Sa | POLYAMINOACIDES FUNCTIONALIZED BY AT LEAST ONE YDROPHOBIC GROUP AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS. |
AU2003902828A0 (en) | 2003-06-05 | 2003-06-26 | Fujisawa Pharmaceutical Co., Ltd. | Dpp-iv inhibitor |
DE10327439A1 (en) | 2003-06-18 | 2005-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Novel imidazopyridazinone and imidazopyridone derivatives, their production and their use as pharmaceuticals |
US7566707B2 (en) * | 2003-06-18 | 2009-07-28 | Boehringer Ingelheim International Gmbh | Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions |
DE602004030244D1 (en) | 2003-06-20 | 2011-01-05 | Hoffmann La Roche | ITOREN |
CN101090901B (en) | 2003-06-20 | 2010-12-15 | 霍夫曼-拉罗奇有限公司 | Hexahydropyridoisoqinolines as DPP-IV inhibitors |
JO2625B1 (en) * | 2003-06-24 | 2011-11-01 | ميرك شارب اند دوم كوربوريشن | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
US7364755B2 (en) | 2003-07-07 | 2008-04-29 | Synthon Ip Inc. | Modified calcium phosphate excipient |
AR045047A1 (en) | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | ARILO AND HETEROARILO DERIVATIVES TRISUSTITUIDOS AS MODULATORS OF METABOLISM AND PROFILAXIS AND TREATMENT OF DISORDERS RELATED TO THEMSELVES |
EP2287165A3 (en) | 2003-07-14 | 2011-06-22 | Arena Pharmaceuticals, Inc. | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
US20050027012A1 (en) | 2003-07-16 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Tablets containing ambroxol |
DE60331236D1 (en) | 2003-07-24 | 2010-03-25 | Eswaran Krishnan Iyer | ORAL COMPOSITIONS FOR THE TREATMENT OF DIABETES |
US6995183B2 (en) | 2003-08-01 | 2006-02-07 | Bristol Myers Squibb Company | Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods |
AU2004261667A1 (en) * | 2003-08-01 | 2005-02-10 | Genelabs Technologies, Inc. | Bicyclic imidazol derivatives against Flaviviridae |
BRPI0413518A (en) | 2003-08-14 | 2006-10-10 | Novo Nordisk Healthcare Ag | aqueous liquid pharmaceutical composition, method for preparing and using same, method for treating a factor responsive syndrome vii, and, airtight container |
EP1667680A4 (en) * | 2003-08-29 | 2008-10-08 | Aton Pharma Inc | Combination methods of treating cancer |
WO2005026148A1 (en) | 2003-09-08 | 2005-03-24 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
ATE534404T1 (en) | 2003-10-03 | 2011-12-15 | Takeda Pharmaceutical | DIPEPTIDYLPEPTIDASE IV INHIBITORS FOR THE TREATMENT OF DIABETES PATIENTS WITH SECONDARY FAILURE DUE TO SULFONYL UREAS |
US7107714B2 (en) | 2003-11-10 | 2006-09-19 | Marketing Displays, Inc. | Portable snap-fit sign stand |
KR20060109911A (en) | 2003-11-17 | 2006-10-23 | 노파르티스 아게 | Use of dipeptidyl peptidase iv inhibitors |
DE10355304A1 (en) * | 2003-11-27 | 2005-06-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Novel 8- (piperazin-1-yl) and 8 - ([1,4] diazepan-1-yl) xanthines, their preparation and their use as pharmaceuticals |
WO2005053695A1 (en) * | 2003-12-04 | 2005-06-16 | Eisai Co., Ltd. | Preventive or therapeutic agent for multiple sclerosis |
US7217711B2 (en) * | 2003-12-17 | 2007-05-15 | Boehringer Ingelheim International Gmbh | Piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutical compositions |
DE10359098A1 (en) | 2003-12-17 | 2005-07-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Novel 2- (piperazin-1-yl) and 2 - ([1,4] diazepan-1-yl) imidazo [4,5-d] pyridazin-4-ones, their preparation and their use as pharmaceuticals |
ATE501135T1 (en) * | 2003-12-18 | 2011-03-15 | Tibotec Pharm Ltd | PIPERIDINAMINO-BENZIMIDAZOLE DERIVATIVES AL RESPIRATORY SYNCYTIALVIRUS REPLICATION INHIBITORS |
DE10360835A1 (en) | 2003-12-23 | 2005-07-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New bicyclic imidazole derivatives are dipeptidylpeptidase-IV inhibitors useful to treat e.g. arthritis, obesity, allograft transplantation and calcitonin-induced osteoporosis |
JP4958560B2 (en) | 2003-12-24 | 2012-06-20 | プロシディオン・リミテッド | Heterocyclic derivatives as GPCR receptor agonists |
US20080234291A1 (en) | 2004-01-21 | 2008-09-25 | Marc Karel Jozef Francois | Mitratapide Oral Solution |
SE0400234D0 (en) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New compounds, methods for their preparation and use thereof |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
DK1758905T3 (en) | 2004-02-18 | 2009-08-24 | Boehringer Ingelheim Int | 8- [3-Amino-piperidin-1-yl] -xanthines, their preparation and their use as DPP-IV inhibitors |
DE102004019540A1 (en) | 2004-04-22 | 2005-11-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Composition, useful for treatment of e.g. inflammatory and obstructive respiratory complaint, sinus rhythm in heart in atrioventricular block and circulatory shock, comprises 6-hydroxy-4H-benzo1,4oxazin-3-one derivatives and other actives |
DE102004009039A1 (en) | 2004-02-23 | 2005-09-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8- [3-Amino-piperidin-1-yl] xanthines, their preparation and use as pharmaceuticals |
EP1593671A1 (en) | 2004-03-05 | 2005-11-09 | Graffinity Pharmaceuticals AG | DPP-IV inhibitors |
US7393847B2 (en) * | 2004-03-13 | 2008-07-01 | Boehringer Ingleheim International Gmbh | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions |
CN102134231B (en) | 2004-03-15 | 2020-08-04 | 武田药品工业株式会社 | Dipeptidyl peptidase inhibitors |
EP2360164A3 (en) | 2004-03-16 | 2012-01-04 | Boehringer Ingelheim International GmbH | Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof |
EP1577306A1 (en) | 2004-03-17 | 2005-09-21 | Boehringer Ingelheim Pharma GmbH & Co.KG | novel benzoxazinone derivatives as slow-acting betamimetics and use thereof in treatment of respiratory tract diseases |
US7179809B2 (en) * | 2004-04-10 | 2007-02-20 | Boehringer Ingelheim International Gmbh | 2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions |
EP1740589A1 (en) | 2004-04-10 | 2007-01-10 | Boehringer Ingelheim International GmbH | Novel 2-amino-imidazo[4,5-d]pyridazin-4-ones and 2-amino-imidazo[4,5-c]pyridin-4-ones, production and use thereof as medicaments |
US20050239778A1 (en) | 2004-04-22 | 2005-10-27 | Boehringer Ingelheim International Gmbh | Novel medicament combinations for the treatment of respiratory diseases |
US20050244502A1 (en) | 2004-04-28 | 2005-11-03 | Mathias Neil R | Composition for enhancing absorption of a drug and method |
JP4976281B2 (en) | 2004-05-03 | 2012-07-18 | オメガ バイオ‐ファーマ(アイ.ピー.3)リミテッド | Materials and methods for regulating metabolism |
US7439370B2 (en) * | 2004-05-10 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides |
EP1753748B1 (en) | 2004-05-12 | 2009-07-29 | Pfizer Products Inc. | Proline derivatives and their use as dipeptidyl peptidase iv inhibitors |
DE102004024454A1 (en) | 2004-05-14 | 2005-12-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Novel enantiomerically pure beta agonists, process for their preparation and their use as pharmaceuticals |
PE20060315A1 (en) | 2004-05-24 | 2006-05-15 | Irm Llc | THIAZOLE COMPOUNDS AS PPAR MODULATORS |
TWI354569B (en) * | 2004-05-28 | 2011-12-21 | Bristol Myers Squibb Co | Coated tablet formulation and method |
EA012281B1 (en) | 2004-06-01 | 2009-08-28 | Арес Трейдинг С.А. | Method of stabilizing proteins |
US7935723B2 (en) | 2004-06-04 | 2011-05-03 | Novartis Pharma Ag | Use of organic compounds |
WO2005120576A2 (en) | 2004-06-09 | 2005-12-22 | Yasoo Health | Composition and method for improving pancreatic islet cell survival |
DE102004030502A1 (en) * | 2004-06-24 | 2006-01-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Novel imidazoles and triazoles, their preparation and use as medicines |
CA2511269A1 (en) | 2004-07-07 | 2006-01-07 | F. Hoffmann-La Roche Ag | Multimarker panel based on p1gf for diabetes type 1 and 2 |
RU2007105346A (en) | 2004-07-14 | 2008-09-27 | Новартис АГ (CH) | COMBINATION OF DPP-IV INHIBITORS AND COMPOUNDS MODULATING 5-HT3-I / OR 5-HT4-RECEPTORS |
JP2006045156A (en) | 2004-08-06 | 2006-02-16 | Sumitomo Pharmaceut Co Ltd | Condensed pyrazole derivative |
TW200613275A (en) | 2004-08-24 | 2006-05-01 | Recordati Ireland Ltd | Lercanidipine salts |
WO2006022428A1 (en) | 2004-08-26 | 2006-03-02 | Takeda Pharmaceutical Company Limited | Remedy for diabetes |
DE102004043944A1 (en) * | 2004-09-11 | 2006-03-30 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Novel 8- (3-amino-piperidin-1-yl) -7- (but-2-ynyl) -xanthines, their preparation and their use as pharmaceuticals |
DE102004044221A1 (en) | 2004-09-14 | 2006-03-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New 3-methyl-7-butynyl xanthines, their preparation and their use as pharmaceuticals |
CN1759834B (en) | 2004-09-17 | 2010-06-23 | 中国医学科学院医药生物技术研究所 | Application of berberine or associated with Simvastatin in preparing product for preventing or curing disease or symptom related to blood fat |
AU2005289881A1 (en) | 2004-09-23 | 2006-04-06 | Amgen Inc. | Substituted sulfonamidopropionamides and methods of use |
KR20070099527A (en) | 2004-10-08 | 2007-10-09 | 노파르티스 아게 | Combination of organic compounds |
AP2007003973A0 (en) | 2004-10-12 | 2007-07-30 | Glenmark Pharmaceuticals Sa | Novel dideptidyl peptidase IV inhibitors, pharmaceutical compositions containing them, and proces for their preparation |
WO2006047248A1 (en) | 2004-10-25 | 2006-05-04 | Novartis Ag | Combination of dpp-iv inhibitor, ppar antidiabetic and metformin |
DE102004054054A1 (en) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines |
DE102005013967A1 (en) | 2004-11-05 | 2006-10-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New imidazole or pyrimidine derivatives are bradykinin B1 antagonists used for treating e.g. pain, stroke, peptic ulcers and other inflammatory disorders |
JP2006137678A (en) | 2004-11-10 | 2006-06-01 | Shionogi & Co Ltd | Interleukin-2 composition |
KR20070090206A (en) | 2004-12-24 | 2007-09-05 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | Bicyclic pyrrole derivatives |
KR100760430B1 (en) | 2004-12-31 | 2007-10-04 | 한미약품 주식회사 | Controlled release complex formulation for oral administration of medicine for diabetes and method for the preparation thereof |
MY148521A (en) | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
DOP2006000008A (en) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | COMBINED THERAPY FOR THE TREATMENT OF DIABETES AND RELATED AFFECTIONS AND FOR THE TREATMENT OF AFFECTIONS THAT IMPROVE THROUGH AN INCREASE IN THE BLOOD CONCENTRATION OF GLP-1 |
GT200600008A (en) | 2005-01-18 | 2006-08-09 | FORMULATION OF DIRECT COMPRESSION AND PROCESS | |
WO2006111169A1 (en) | 2005-04-21 | 2006-10-26 | Gastrotech Pharma A/S | Pharmaceutical preparations of a glp-1 molecule and an anti-emetic drug |
ZA200708179B (en) | 2005-04-22 | 2009-12-30 | Alantos Pharmaceuticals Holding Inc | Dipeptidyl peptidase-IV inhibitors |
UA91546C2 (en) | 2005-05-03 | 2010-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Crystalline form of 1-chloro-4-(я-d-glucopyranos-1-yl)-2-[4-((s)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
TW200716557A (en) | 2005-05-25 | 2007-05-01 | Wyeth Corp | Methods of synthesizing substituted 3-cyanoquinolines and intermediates thereof |
KR101438234B1 (en) | 2005-06-03 | 2014-09-04 | 미쓰비시 타나베 파마 코퍼레이션 | Concomitant pharmaceutical agents and use thereof |
GT200600218A (en) | 2005-06-10 | 2007-03-28 | FORMULATION AND PROCESS OF DIRECT COMPRESSION | |
KR101374304B1 (en) | 2005-06-20 | 2014-03-14 | 디코드 제네틱스 이에이치에프 | Genetic variants in the TCF7L2 gene as diagnostic markers for risk of type 2 diabetes mellitus |
PE20070374A1 (en) | 2005-07-08 | 2007-05-12 | Pfizer Ltd | ANTI-MADCAM ANTIBODIES |
UY29694A1 (en) | 2005-07-28 | 2007-02-28 | Boehringer Ingelheim Int | METHODS TO PREVENT AND TREAT METABOLIC AND NEW DISORDERS DERIVED FROM PIRAZOL-O-GLUCOSIDO |
DE102005035891A1 (en) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8- (3-amino-piperidin-1-yl) -xanthines, their preparation and their use as pharmaceuticals |
BRPI0614732A2 (en) * | 2005-08-11 | 2011-04-12 | Hoffmann La Roche | A pharmaceutical composition comprising a dpp-iv inhibitor, use of a dpp-iv inhibitor and method for treating diseases associated with high blood glucose levels. |
EP1760076A1 (en) | 2005-09-02 | 2007-03-07 | Ferring B.V. | FAP Inhibitors |
PL1942898T5 (en) | 2005-09-14 | 2014-10-31 | Takeda Pharmaceuticals Co | Dipeptidyl peptidase inhibitors for treating diabetes |
GEP20135791B (en) | 2005-09-14 | 2013-03-25 | Takeda Pharmaceutical | Use of dipeptidyl peptidase inhibitors |
MX2008003634A (en) | 2005-09-16 | 2009-10-08 | Arena Pharm Inc | Modulators of metabolism and the treatment of disorders related thereto. |
RU2440143C2 (en) | 2005-09-20 | 2012-01-20 | Новартис Аг | Application of dpp-iv inhibitor for reduction of glycemia acute exacerbation |
EP1945190A1 (en) | 2005-09-22 | 2008-07-23 | Swissco Devcelopment AG | Effervescent metformin composition and tablets and granules made therefrom |
JOP20180109A1 (en) | 2005-09-29 | 2019-01-30 | Novartis Ag | New Formulation |
JP2009510112A (en) | 2005-09-30 | 2009-03-12 | ノバルティス アクチエンゲゼルシャフト | Combination of organic compounds |
US20090156579A1 (en) | 2005-10-25 | 2009-06-18 | Hasegawa Philip A | Combination of a Dipeptidyl Peptidase-4 Inhibitor and an Anti-Hypertensive Agent for the Treatment of Diabetes and Hypertension |
CN101300298A (en) | 2005-11-04 | 2008-11-05 | Ls电线有限公司 | Synthesis of mdh-polymer hybrid particles |
JP5165582B2 (en) | 2005-12-16 | 2013-03-21 | メルク・シャープ・エンド・ドーム・コーポレイション | Pharmaceutical composition comprising a combination of a dipeptidyl peptidase-4 inhibitor and metformin |
RU2008129873A (en) | 2005-12-23 | 2010-01-27 | Новартис АГ (CH) | CONDENSED HETEROCYCLIC COMPOUNDS USEFUL AS DPP-IV INHIBITORS |
GB0526291D0 (en) | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
BRPI0706423A2 (en) | 2006-01-06 | 2011-03-29 | Novartis Ag | use of organic compounds |
AU2007216452A1 (en) | 2006-02-15 | 2007-08-23 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture |
WO2007099345A1 (en) | 2006-03-02 | 2007-09-07 | Betagenon Ab | Medical use of bmp-2 and/ or bmp-4 |
PE20071221A1 (en) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | GPR119 RECEPTOR AGONISTS IN METHODS TO INCREASE BONE MASS AND TO TREAT OSTEOPOROSIS AND OTHER CONDITIONS CHARACTERIZED BY LOW BONE MASS, AND COMBINED THERAPY RELATED TO THESE AGONISTS |
US8455435B2 (en) | 2006-04-19 | 2013-06-04 | Ludwig-Maximilians-Universitat Munchen | Remedies for ischemia |
BRPI0711558A2 (en) | 2006-05-04 | 2011-11-08 | Boeringer Ingelheim Internat Gmbh | polymorphs |
PE20080251A1 (en) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | USES OF DPP IV INHIBITORS |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
EP2020996B1 (en) | 2006-05-16 | 2011-11-23 | Gilead Sciences, Inc. | Method and compositions for treating hematological malignancies |
KR20070111099A (en) | 2006-05-16 | 2007-11-21 | 영진약품공업주식회사 | Novel crystalline form of sitagliptin hydrochloride |
WO2007137107A2 (en) | 2006-05-19 | 2007-11-29 | Abbott Laboratories | Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme |
KR100858848B1 (en) | 2006-05-23 | 2008-09-17 | 한올제약주식회사 | Pharmaceutical compositions and formulations of Metformin extended release tablets |
WO2007149797A2 (en) | 2006-06-19 | 2007-12-27 | Novartis Ag | Use of organic compounds |
WO2007148185A2 (en) | 2006-06-21 | 2007-12-27 | Pfizer Products Inc. | Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors |
AT503443B1 (en) | 2006-06-23 | 2007-10-15 | Leopold Franzens Uni Innsbruck | Preparation of an ice surface, useful for ice rink, and ice sports cars and trains, comprises freezing water in which an inorganic substance e.g. ammonia, alkali hydroxide, hydrogen halide, nitric acid and sulfuric acid, is added |
TW200811147A (en) | 2006-07-06 | 2008-03-01 | Arena Pharm Inc | Modulators of metabolism and the treatment of disorders related thereto |
TW200811140A (en) | 2006-07-06 | 2008-03-01 | Arena Pharm Inc | Modulators of metabolism and the treatment of disorders related thereto |
JP2010500326A (en) | 2006-08-08 | 2010-01-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Pyrrolo [3,2-D] pyrimidine as a DPP-IV inhibitor for the treatment of diabetes |
JP5384343B2 (en) | 2006-08-15 | 2014-01-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and methods for their preparation |
US20100227809A1 (en) | 2006-08-17 | 2010-09-09 | Wellstat Therapeutics Corporation | Combination treatment for metabolic disorders |
DE102006042586B4 (en) | 2006-09-11 | 2014-01-16 | Betanie B.V. International Trading | Process for the microparticulate loading of high polymer carbohydrates with hydrophobic active fluids |
US7956201B2 (en) | 2006-11-06 | 2011-06-07 | Hoffman-La Roche Inc. | Process for the preparation of (S)-4-fluoromethyl-dihydro-furan-2-one |
CA2668623A1 (en) | 2006-11-06 | 2008-05-15 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture |
TWI448291B (en) | 2006-11-09 | 2014-08-11 | Boehringer Ingelheim Int | Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions |
UA97817C2 (en) | 2006-12-06 | 2012-03-26 | Глаксосмиткляйн Ллк | Heterocyclic derivatives of 4-(methylsulfonyl)phenyl and use thereof |
ES2319596B1 (en) | 2006-12-22 | 2010-02-08 | Laboratorios Almirall S.A. | NEW DERIVATIVES OF THE AMINO-NICOTINIC AND AMINO-ISONICOTINIC ACIDS. |
US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
AR064736A1 (en) | 2007-01-04 | 2009-04-22 | Prosidion Ltd | GPCR AGONISTS |
CL2008000133A1 (en) | 2007-01-19 | 2008-05-23 | Boehringer Ingelheim Int | PHARMACEUTICAL COMPOSITION THAT INCLUDES A COMPOUND DERIVED FROM PIRAZOL-O-GLUCOSIDE COMBINED WITH AT LEAST A SECOND THERAPEUTIC AGENT; AND USE OF THE COMPOSITION FOR THE TREATMENT OF MELLITUS DIABETES, CATARATS, NEUROPATHY, MYOCARDIAL INFARTS, AND |
AR065096A1 (en) | 2007-02-01 | 2009-05-13 | Takeda Pharmaceutical | SOLID PREPARATION |
CA2677201C (en) | 2007-02-01 | 2015-11-17 | Takeda Pharmaceutical Company Limited | Solid preparation comprising alogliptin and pioglitazone |
EP2118051B1 (en) | 2007-02-06 | 2011-05-04 | Chelsea Therapeutics, Inc. | New compounds, methods for their preparation and use thereof |
CA2681092A1 (en) | 2007-03-15 | 2008-09-18 | Nectid, Inc. | Anti-diabetic combinations comprising a slow release biguanide composition and an immediate release dipeptidyl peptidase iv inhibitor composition |
KR101361427B1 (en) | 2007-04-03 | 2014-02-10 | 미쓰비시 타나베 파마 코퍼레이션 | Combined use of dipeptidyl peptidase iv inhibitor compound and sweetener |
WO2008130998A2 (en) | 2007-04-16 | 2008-10-30 | Smith & Nephew, Inc. | Powered surgical system |
PE20090696A1 (en) | 2007-04-20 | 2009-06-20 | Bristol Myers Squibb Co | CRYSTALLINE FORMS OF SAXAGLIPTIN AND PROCESSES FOR PREPARING THEM |
EP2144902B1 (en) | 2007-05-04 | 2012-05-16 | Bristol-Myers Squibb Company | [6,6]and [6,7]-bicyclic gpr119 g protein-coupled receptor agonists |
US8440172B2 (en) | 2007-07-09 | 2013-05-14 | Symrise Ag | Stable soluble salts of phenylbenzimidazole sulfonic acid at PHS at or below 7.0 |
WO2009011451A1 (en) | 2007-07-19 | 2009-01-22 | Takeda Pharmaceutical Company Limited | Solid preparation comprising alogliptin and metformin hydrochloride |
PE20090938A1 (en) | 2007-08-16 | 2009-08-08 | Boehringer Ingelheim Int | PHARMACEUTICAL COMPOSITION INCLUDING A BENZENE DERIVATIVE SUBSTITUTED WITH GLUCOPYRANOSIL |
CL2008002424A1 (en) | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Pharmaceutical composition comprising a compound derived from pyrazole-o-glucoside; and use of the pharmaceutical composition for the treatment of diabetes mellitus, abnormal glucose tolerance and hyperglycemia, metabolic disorders, among others. |
UY31291A1 (en) | 2007-08-16 | 2009-03-31 | PHARMACEUTICAL COMPOSITION THAT INCLUDES A DERIVATIVE OF PIRAZOL-0-GLUCOSIDO | |
PE20090603A1 (en) | 2007-08-16 | 2009-06-11 | Boehringer Ingelheim Int | PHARMACEUTICAL COMPOSITION INCLUDING A SGLT2 INHIBITOR AND A DPP IV INHIBITOR |
RU2569749C2 (en) | 2007-08-17 | 2015-11-27 | Бёрингер Ингельхайм Интернациональ Гмбх | Purine derivatives applicable for treating fap-related (fibroblast activator protein) diseases |
WO2009037719A1 (en) | 2007-09-21 | 2009-03-26 | Lupin Limited | Novel compounds as dipeptidyl peptidase iv (dpp iv) inhibitors |
PT2597103T (en) | 2007-11-16 | 2017-02-08 | Novo Nordisk As | Stable pharmaceutical compositions comprising liraglutide and degludec |
CN101234105A (en) | 2008-01-09 | 2008-08-06 | 北京润德康医药技术有限公司 | Pharmaceutical composition containing diabetosan and vildagliptin and preparation thereof |
US20090186086A1 (en) | 2008-01-17 | 2009-07-23 | Par Pharmaceutical, Inc. | Solid multilayer oral dosage forms |
CL2008003653A1 (en) | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Use of a glucopyranosyl-derived sglt inhibitor and a selected dppiv inhibitor to treat diabetes; and pharmaceutical composition. |
TW200936136A (en) | 2008-01-28 | 2009-09-01 | Sanofi Aventis | Tetrahydroquinoxaline urea derivatives, their preparation and their therapeutic application |
US20100330177A1 (en) | 2008-02-05 | 2010-12-30 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor |
AU2009220444A1 (en) | 2008-03-04 | 2009-09-11 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-IV inhibitor |
CN102015641B (en) | 2008-03-05 | 2014-01-01 | 武田药品工业株式会社 | Heterocyclic compound |
US8551524B2 (en) | 2008-03-14 | 2013-10-08 | Iycus, Llc | Anti-diabetic combinations |
JP5711655B2 (en) | 2008-03-31 | 2015-05-07 | シマベイ セラピューティクス, インコーポレーテッド | Oxymethylene aryl compounds and uses thereof |
AR071175A1 (en) | 2008-04-03 | 2010-06-02 | Boehringer Ingelheim Int | PHARMACEUTICAL COMPOSITION THAT INCLUDES AN INHIBITOR OF DIPEPTIDIL-PEPTIDASA-4 (DPP4) AND A COMPARING PHARMACO |
CN101590007A (en) | 2008-05-27 | 2009-12-02 | 北京瑞伊人科技发展有限公司 | A kind of metformin hydrochloride/voigelibo sugar-lowering oral preparation compositions and preparation thereof |
PE20100156A1 (en) | 2008-06-03 | 2010-02-23 | Boehringer Ingelheim Int | NAFLD TREATMENT |
KR20190016601A (en) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | Treatment for diabetes in patients inappropriate for metformin therapy |
UY32030A (en) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN" |
AU2009281122C1 (en) | 2008-08-15 | 2016-04-21 | Boehringer Ingelheim International Gmbh | Purin derivatives for use in the treatment of fab-related diseases |
JP2010053576A (en) | 2008-08-27 | 2010-03-11 | Sumitomo Forestry Co Ltd | Mat for paving |
EP2344195A2 (en) | 2008-09-10 | 2011-07-20 | Boehringer Ingelheim International GmbH | Combination therapy for the treatment of diabetes and related conditions |
UY32177A (en) | 2008-10-16 | 2010-05-31 | Boehringer Ingelheim Int | TREATMENT OF DIABETES IN PATIENTS WITH INSUFFICIENT GLUCEMIC CONTROL TO WEIGHT THERAPY WITH DRUG, ORAL OR NOT, ANTIDIABÉTICO |
WO2010045656A2 (en) | 2008-10-17 | 2010-04-22 | Nectid, Inc. | Novel sglt2 inhibitor dosage forms |
JP2012512848A (en) | 2008-12-23 | 2012-06-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Salt forms of organic compounds |
TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
AR075204A1 (en) | 2009-01-29 | 2011-03-16 | Boehringer Ingelheim Int | DPP-4 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, USEFUL TO TREAT METABOLIC DISEASES IN PEDIATRIC PATIENTS, PARTICULARLY MELLITUS DIABETES TYPE 2 |
UY32427A (en) | 2009-02-13 | 2010-09-30 | Boheringer Ingelheim Internat Gmbh | PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL FORM, PROCEDURE FOR PREPARATION, METHODS OF TREATMENT AND USES OF THE SAME |
JP2012517977A (en) | 2009-02-13 | 2012-08-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | An anti-diabetic drug comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other anti-diabetic drugs |
ES2797503T3 (en) | 2009-02-13 | 2020-12-02 | Boehringer Ingelheim Int | Pharmaceutical composition comprising an SGLT2 inhibitor, a DPP-IV inhibitor and optionally an additional antidiabetic agent and their uses |
TW201031661A (en) | 2009-02-17 | 2010-09-01 | Targacept Inc | Fused benzazepines as neuronal nicotinic acetylcholine receptor ligands |
EP2408780A2 (en) | 2009-03-20 | 2012-01-25 | Pfizer Inc. | 3-oxa-7-azabicycloý3.3.1¨nonanes |
US8815292B2 (en) | 2009-04-27 | 2014-08-26 | Revalesio Corporation | Compositions and methods for treating insulin resistance and diabetes mellitus |
WO2010126908A1 (en) | 2009-04-27 | 2010-11-04 | Revalesio Corporation | Compositions and methods for treating insulin resistance and diabetes mellitus |
US20120100221A1 (en) | 2009-06-02 | 2012-04-26 | Ranbaxy Laboratories Limited | Pharmaceutical compositions containing a combination of an antihistamine and a decongestant |
US20120059011A1 (en) | 2009-06-15 | 2012-03-08 | Nicholas Birringer | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone |
RU2733410C2 (en) | 2009-07-21 | 2020-10-01 | Керикс Байофармасьютикалз, Инк. | Medicinal forms of ferric citrate (iii) |
PT2482812T (en) | 2009-10-02 | 2023-01-24 | Boehringer Ingelheim Int | Therapeutic uses of pharmaceutical compositions |
US10610489B2 (en) | 2009-10-02 | 2020-04-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
JP5446716B2 (en) | 2009-10-21 | 2014-03-19 | 大正製薬株式会社 | Method for producing tablets containing arginine and carnitine |
KR20210033559A (en) | 2009-11-27 | 2021-03-26 | 베링거 인겔하임 인터내셔날 게엠베하 | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
JP2010070576A (en) | 2009-12-28 | 2010-04-02 | Sato Pharmaceutical Co Ltd | Rapidly soluble tablet |
TWI562775B (en) | 2010-03-02 | 2016-12-21 | Lexicon Pharmaceuticals Inc | Methods of using inhibitors of sodium-glucose cotransporters 1 and 2 |
EP2547339A1 (en) | 2010-03-18 | 2013-01-23 | Boehringer Ingelheim International GmbH | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
AU2011249771A1 (en) | 2010-05-05 | 2012-11-01 | Boehringer Ingelheim International Gmbh | Pharmaceutical formulations comprising pioglitazone and linagliptin |
US9186392B2 (en) | 2010-05-05 | 2015-11-17 | Boehringer Ingelheim International Gmbh | Combination therapy |
EP2579879B1 (en) | 2010-06-09 | 2016-03-23 | Poxel | Triazine derivatives for delaying the onset of type 1 diabetes |
JP2013533241A (en) | 2010-06-22 | 2013-08-22 | ティダブリューアイ・ファーマシューティカルズ・インコーポレイテッド | Controlled release composition with reduced food effect |
CA2803504C (en) | 2010-06-24 | 2022-08-30 | Boehringer Ingelheim International Gmbh | A combination for diabetes therapy comprising linagliptin and a long-acting insulin |
EP2611442B1 (en) | 2010-09-03 | 2018-07-04 | Bristol-Myers Squibb Company | Drug formulations using water soluble antioxidants |
WO2012039420A1 (en) | 2010-09-21 | 2012-03-29 | 国立大学法人九州大学 | Bionic aortic baroreflex system for treating disease associated with aortic baroreflex dysfunction |
AR083878A1 (en) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | VASOPROTECTORA AND CARDIOPROTECTORA ANTIDIABETIC THERAPY, LINAGLIPTINA, TREATMENT METHOD |
WO2012088682A1 (en) | 2010-12-29 | 2012-07-05 | Shanghai Fochon Pharmaceutical Co Ltd. | 2-(3-aminopiperidin-1-yl)-[1,2,4]triazolo[1,5-c]pyrimidine-5,7(3h,6h)-dione derivates as dipeptidyl peptidase iv(dpp-iv) inhibitors |
ES2801725T3 (en) | 2011-02-01 | 2021-01-12 | Bristol Myers Squibb Co | Pharmaceutical formulations that include an amine compound |
AR085689A1 (en) | 2011-03-07 | 2013-10-23 | Boehringer Ingelheim Int | PHARMACEUTICAL COMPOSITIONS OF METFORMIN, LINAGLIPTINE AND AN SGLT-2 INHIBITOR |
EA023330B1 (en) | 2011-05-10 | 2016-05-31 | Сандоз Аг | Polymorph of linagliptin benzoate |
CA2841552C (en) | 2011-07-15 | 2020-06-23 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
US20130172244A1 (en) | 2011-12-29 | 2013-07-04 | Thomas Klein | Subcutaneous therapeutic use of dpp-4 inhibitor |
CA2860650C (en) | 2012-01-04 | 2016-08-02 | The Procter & Gamble Company | Active containing fibrous structures with multiple regions |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
WO2013171166A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis |
EP2849755A1 (en) | 2012-05-14 | 2015-03-25 | Boehringer Ingelheim International GmbH | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
JP6374862B2 (en) | 2012-05-24 | 2018-08-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Xanthine derivatives as DPP-4 inhibitors for use in the treatment of autoimmune diabetes, particularly LADA |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
WO2013174769A1 (en) | 2012-05-25 | 2013-11-28 | Boehringer Ingelheim International Gmbh | Use of keratinocytes as a biologically active substance in the treatment of wounds, such as diabetic wounds, optionally in combination with a dpp-4 inhibitor |
WO2013179307A2 (en) | 2012-05-29 | 2013-12-05 | Mylan Laboratories Limited | Stabilized pharmaceutical compositions of saxagliptin |
BR112015003067A2 (en) | 2012-08-24 | 2017-07-04 | Novartis Ag | nep inhibitors to treat diseases characterized by atrial enlargement or remodeling |
JP2015533133A (en) | 2012-10-09 | 2015-11-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Use of moisture-control disintegrants in tablet manufacture |
US20140100236A1 (en) | 2012-10-09 | 2014-04-10 | Boehringer Ingelheim International Gmbh | Use of selectively moisture-adjusted tabletting material in the production of mechanically stable tablets which contain at least one hydrate-forming active substance and/or adjuvant relevant to the mechanical stability of the tablets, particularly arginine-containing tablets |
US9050302B2 (en) | 2013-03-01 | 2015-06-09 | Jazz Pharmaceuticals Ireland Limited | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
EP2968344A1 (en) | 2013-03-15 | 2016-01-20 | Boehringer Ingelheim International GmbH | Use of linagliptin in cardio- and renoprotective antidiabetic therapy |
MX2021004308A (en) | 2013-04-18 | 2022-10-26 | Boehringer Ingelheim Int | Pharmaceutical composition, methods for treating and uses thereof. |
JP2016518438A (en) | 2013-05-17 | 2016-06-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Combination of DPP-4 inhibitor and α-glucosidase inhibitor |
CN105283187A (en) | 2013-06-14 | 2016-01-27 | 勃林格殷格翰国际有限公司 | Dpp-4 inhibitors for treating diabetes and its complications |
ES2950384T3 (en) | 2014-02-28 | 2023-10-09 | Boehringer Ingelheim Int | Medical use of a DPP-4 inhibitor |
CN104130258B (en) | 2014-08-13 | 2016-06-01 | 广东东阳光药业有限公司 | The method for transformation of a kind of dimer |
WO2016059219A1 (en) | 2014-10-17 | 2016-04-21 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
CA3022202A1 (en) | 2016-06-10 | 2017-12-14 | Boehringer Ingelheim International Gmbh | Combinations of linagliptin and metformin |
-
2006
- 2006-05-04 EP EP06009201A patent/EP1852108A1/en not_active Withdrawn
-
2007
- 2007-04-30 EP EP15158445.5A patent/EP2910241A1/en not_active Withdrawn
- 2007-04-30 ES ES10175638T patent/ES2527409T4/en active Active
- 2007-04-30 AT AT07728658T patent/ATE480228T1/en active
- 2007-04-30 EA EA201100958A patent/EA029890B1/en not_active IP Right Cessation
- 2007-04-30 EP EP07728658A patent/EP2023902B8/en active Active
- 2007-04-30 KR KR1020177035865A patent/KR102051281B1/en active IP Right Review Request
- 2007-04-30 RS RSP-2010/0457A patent/RS51466B/en unknown
- 2007-04-30 HU HUE10175188A patent/HUE025210T2/en unknown
- 2007-04-30 WO PCT/EP2007/054204 patent/WO2007128724A1/en active Application Filing
- 2007-04-30 PL PL10175638T patent/PL2283819T3/en unknown
- 2007-04-30 NZ NZ613426A patent/NZ613426A/en unknown
- 2007-04-30 PT PT101756385T patent/PT2283819E/en unknown
- 2007-04-30 ME MEP-2010-172A patent/ME01170B/en unknown
- 2007-04-30 CN CN201210068456.2A patent/CN102526737B/en not_active Expired - Fee Related
- 2007-04-30 JP JP2009508327A patent/JP5478244B2/en active Active
- 2007-04-30 MX MX2008013958A patent/MX2008013958A/en active IP Right Grant
- 2007-04-30 EP EP10175188.1A patent/EP2277509B1/en not_active Revoked
- 2007-04-30 DE DE602007009091T patent/DE602007009091D1/en active Active
- 2007-04-30 ME MEP-2014-136A patent/ME01941B/en unknown
- 2007-04-30 DK DK10175188.1T patent/DK2277509T5/en active
- 2007-04-30 SG SG201103141-6A patent/SG171649A1/en unknown
- 2007-04-30 MY MYPI20084341A patent/MY146969A/en unknown
- 2007-04-30 EP EP10175638.5A patent/EP2283819B9/en not_active Revoked
- 2007-04-30 EA EA200802184A patent/EA016559B1/en unknown
- 2007-04-30 NZ NZ595983A patent/NZ595983A/en unknown
- 2007-04-30 PT PT07728658T patent/PT2023902E/en unknown
- 2007-04-30 DK DK10175638.5T patent/DK2283819T3/en active
- 2007-04-30 BR BRPI0722388-9A patent/BRPI0722388B1/en active IP Right Grant
- 2007-04-30 KR KR1020167029877A patent/KR101855323B1/en active IP Right Review Request
- 2007-04-30 DK DK07728658.1T patent/DK2023902T3/en active
- 2007-04-30 ES ES10175188.1T patent/ES2538818T3/en active Active
- 2007-04-30 AU AU2007247193A patent/AU2007247193B2/en active Active
- 2007-04-30 UA UAA200813472A patent/UA94942C2/en unknown
- 2007-04-30 PL PL07728658T patent/PL2023902T4/en unknown
- 2007-04-30 MX MX2011004033A patent/MX358617B/en unknown
- 2007-04-30 NZ NZ572862A patent/NZ572862A/en unknown
- 2007-04-30 BR BRPI0711179-7A patent/BRPI0711179B1/en active IP Right Grant
- 2007-04-30 RS RSP20140606 patent/RS53570B1/en unknown
- 2007-04-30 SI SI200730434T patent/SI2023902T1/en unknown
- 2007-04-30 KR KR20087026969A patent/KR101478983B1/en active IP Right Review Request
- 2007-04-30 PL PL10175188T patent/PL2277509T3/en unknown
- 2007-04-30 CN CN2007800162273A patent/CN101437493B/en active Active
- 2007-04-30 KR KR1020147011768A patent/KR20140063896A/en not_active Application Discontinuation
- 2007-04-30 ES ES07728658T patent/ES2348576T3/en active Active
- 2007-04-30 CA CA2649922A patent/CA2649922C/en active Active
- 2007-04-30 KR KR1020157022377A patent/KR101710881B1/en active IP Right Review Request
- 2007-04-30 SI SI200731572T patent/SI2283819T1/en unknown
- 2007-05-02 PE PE2007000538A patent/PE20080698A1/en not_active Application Discontinuation
- 2007-05-02 PE PE2011000193A patent/PE20110666A1/en active IP Right Grant
- 2007-05-03 TW TW096115808A patent/TWI474843B/en active
- 2007-05-03 TW TW103100247A patent/TWI520753B/en active
- 2007-05-03 UY UY30319A patent/UY30319A1/en not_active Application Discontinuation
- 2007-05-04 AR ARP070101929A patent/AR060755A1/en unknown
- 2007-05-04 US US11/744,701 patent/US20080107731A1/en not_active Abandoned
-
2008
- 2008-10-01 ZA ZA200808361A patent/ZA200808361B/en unknown
- 2008-10-07 EC EC2008008800A patent/ECSP088800A/en unknown
- 2008-10-10 NO NO20084256A patent/NO343067B1/en unknown
- 2008-10-30 MY MYPI2011001739A patent/MY148496A/en unknown
- 2008-10-30 IL IL195030A patent/IL195030A/en unknown
-
2009
- 2009-11-13 HK HK12113310.2A patent/HK1172549A1/en unknown
- 2009-11-13 HK HK09110601.1A patent/HK1130442A1/en unknown
-
2010
- 2010-09-14 HR HR20100507T patent/HRP20100507T1/en unknown
- 2010-11-30 CY CY20101101096T patent/CY1111354T1/en unknown
-
2011
- 2011-01-19 AR ARP110100165A patent/AR079930A2/en unknown
- 2011-05-12 IL IL212841A patent/IL212841A0/en unknown
- 2011-09-12 US US13/230,133 patent/US20120003313A1/en not_active Abandoned
-
2012
- 2012-01-04 JP JP2012000293A patent/JP6100998B2/en active Active
- 2012-05-09 US US13/467,505 patent/US20120219622A1/en not_active Abandoned
- 2012-09-12 CL CL2012002522A patent/CL2012002522A1/en unknown
- 2012-09-12 CL CL2012002521A patent/CL2012002521A1/en unknown
-
2013
- 2013-01-07 US US13/735,078 patent/US20130122089A1/en not_active Abandoned
- 2013-07-11 JP JP2013145188A patent/JP2013227338A/en active Pending
-
2015
- 2015-01-02 CY CY20151100002T patent/CY1116064T1/en unknown
- 2015-01-05 HR HRP20150003TT patent/HRP20150003T2/en unknown
- 2015-10-07 US US14/877,019 patent/US20160022687A1/en not_active Abandoned
-
2016
- 2016-02-24 JP JP2016033423A patent/JP6564720B2/en active Active
-
2017
- 2017-07-20 US US15/655,269 patent/US20170312287A1/en not_active Abandoned
- 2017-11-10 JP JP2017217311A patent/JP7084711B2/en active Active
-
2019
- 2019-03-19 US US16/357,357 patent/US11033552B2/en active Active
-
2020
- 2020-02-28 JP JP2020033173A patent/JP6987908B2/en active Active
-
2021
- 2021-05-13 US US17/319,325 patent/US20210260068A1/en active Pending
-
2022
- 2022-03-15 JP JP2022040337A patent/JP2022075826A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030016657A1 (en) * | 2001-07-19 | 2003-01-23 | International Business Machines Corporation | Instant messaging with voice conversation feature |
US20040009751A1 (en) * | 2002-07-11 | 2004-01-15 | Oliver Michaelis | Interface selection in a wireless communication network |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11033552B2 (en) | DPP IV inhibitor formulations | |
JP2009535376A6 (en) | DPP IV inhibitor formulation | |
JP2013227338A6 (en) | DPP IV inhibitor formulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |